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ABBREVIATIONS 
 
 Axial diffusion coefficent
  Radial diffusion coefficent
2D 2-dimensional
3D 3-dimensional
AA Anaplastic astrocytomas
ADC Apparent diffusion coefficient
ADCe Apparent diffusion coefficient in peritumoral edema
ADCn Apparent diffusion coefficient in contralateral normal-appearing white matter
ADCt Apparent diifusion coefficient in tumor
ADCe ratio Apparent diffusion coefficient ratio edema/contralateral normal-appearing white matter
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ATP Adenosine triphosphate 
AUC Area under the curve
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BLS Baseline substraction
CBF Cerebral blood flow
CBV Cerebral blood volume
Cho Choline
CL Linear tensor shape
CNI Cho/NAA statistical index
CNS Central nervous system
Cr Creatine
CP Planar tensor shape
CS Spherical tensor shape
CSI Chemical shift imaging
CT Computed tomography
DSC MRI Dynamic susceptibility-weighted contrast-enhanced perfusion MRI
DCE MRI T1-weighted steady-state dynamic contrast-enhanced perfusion MRI
DWI Diffusion-weighted MRI
DTI Diffusion tensor imaging
EPI Echo-planar imaging
FID Free induction decay
FA Fractional anisotropy
FSE Fast spin echo
FOV Field of view
GBM Glioblastoma multiforme
Gd Gadolinium
Gln Glutamine
Glu Glutamate
Glx composed peak of Glu and Gln
GPC Glycerophosphocoline
GRE Gradient echo
HGG High-grade glioma
Kep  Rate constant between extravascular, extracellular space and plasma
Ktrans Volume transfer constant between plasma and extravascular, extracellular space
Lac Lactate
LiCL Lithium chloride
Lip Lipid
LGG Low-grade glioma
LL Combined lipid/lactate
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Max Maximum
MD Mean diffusivity
MI Myo-inositol
MR Magnetic resonance
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
MRSI Magnetic resonance spectroscopic imaging
MVD Microvascular density
MVCP Microvascular cellular proliferation
MVL Microvascular leakage
NAA N-acetyl aspartate
NAAG N-acetylaspartyl glutamate
NMR Nuclear magnetic resonance
NMR-2 Matrix metalloproteinase-2
NPV Negative predictive value
PCNSL Primary central nervous system lymphoma
PCr Phosphocreatine
PLD Preload dosing
PPV Positive predictive value
PRESS Point resolved surface coil spectroscopy
PS The product of permeability surface area
RA Relative anisotropy
rCBV Relative cerebral blood volume
rCBF Relative cerebral blood flow
rCBVt Cerebral blood volume tumor/normal tissue
rCBFt Cerebral blood flow tumor/normal tissue
rCBVe Cerebral blood volume peri-enhancing region/normal tissue
rCBFe Cerebral blood flow peri-enhancing region/normal tissue
rCBVt/e Cerebral blood volume tumor/peri-enhancing region
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RF Radio frequency
ROC Receiver operator characteristic
ROI Region of interest
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SI Signal intensity
SNR Signal-to-noise-ratio
STEAM Stimulated echo acquisition mode
SVS Single-voxel spectroscopy
T1 Longitudinal relaxation time in units of ms
T2 Transverser relaxation time in units of ms
T2* Effective transverse relaxation time in units of ms
TE Echo time in unit of ms
TI Inversion time
TR Repetition time in unit of ms
VOI Volume of interest
VASO Vascular space occupancy imaging
VEGF Vascular endothelial growth factor
WHO World Health Organization
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INTRODUCTION 
 
Brain tumors comprise some of the most malignant tumors known to affect human beings 
and are generally refractory to all modalities of treatment (1). The number of new cases of 
tumors in the central nervous system (CNS) in 2008 in Norway according to the Norwegian 
Cancer Registry was of 1067. Of this group, 367 have malignant tumors, with incidence rates 
of 5.9 to 7.6 cases per100 000 population (2). Malignant brain tumors are the leading cause 
of death from solid tumors in children and the third-leading cause of cancer-related death in 
patients aged 15 to 34 years old (3,4). Brain metastases are the most common complication 
of systemic cancer, with estimated incidence rates of 8.3 to 11 cases per100 000 population 
(1). 
 
The current standard of neuroimaging for brain tumor evaluation is anatomy-based 
magnetic resonance imaging (MRI) with intravenous contrast material (5,6). Unfortunately, 
contrast-enhanced MRI does not fully reflect the complicated biology of infiltrative gliomas 
and has a limited capacity to differentiate a high-grade glioma (HGG) from a single brain 
metastasis. In addition, anatomic MRI suffers from nonspecificity. 
 
Grading of gliomas is important for the determination of appropriate treatment strategies 
(7,8) and in the assessment of prognosis (9), because HGGs are usually treated with tumor 
resection and additional radiotherapy and chemotherapy, whereas in low-grade gliomas 
(LGGs), only surgical treatment for histologic confirmation or tumor resection is performed 
in most patients (10,11,12). The current criterion standard for tumor grading is 
histopathological assessment using the presence of one or more criteria, such as nuclear 
atypia, mitosis, vascular endothelial proliferation and necrosis (8). However, histologic 
grading of primary gliomas with neuropathology has some limitations, such as: 1) Because 
only a few small samples of tissue are assessed, particularly from stereotactic biopsy, the 
most malignant portion of a tumor may not be sampled. 2) It may be difficult to obtain a 
range of samples if the tumor is inaccessible to the surgeon (in eloquent brain). 3) There are 
numerous classifications/grading systems used between different institutions. 4) The 
dynamic nature of CNS tumors, with at least 50% dedifferentiating into more malignant 
grades (13,14,15). Notwithstanding, despite these shortcomings, the World Health 
Organization (WHO) classification scheme remains the standard reference for guiding 
therapy and predicting prognosis in patients with brain tumors (13) (Figure 1). 
 
It is clinically important to distinguish glioblastoma multiforme (GBM) from a single brain 
metastasis, because medical staging, surgical planning, and therapeutic decisions are vastly 
different for each tumor type and could potentially affect the clinical outcome (16,17). 
 
In the last decade, the development and application of various advanced MRI techniques 
have increased such as diffusion-weighted MRI (DWI), diffusion-tensor MRI (DTI) and fiber 
tractography, perfusion and permeability MRI, and proton MR spectroscopy (MRS). 
 
Diffusion is defined as the process of random molecular thermal motion occurring at a 
microscopic scale (18). The apparent diffusion coefficient (ADC) is a value that describes 
microscopic water diffusibility in the presence of factors that restrict diffusion within tissues. 
Measurements of the ADC would be expected to be useful in tumor assessment because 
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variations in water content, which can be found within tumor for various reasons (eg, 
necrosis, variation in cellularity) and adjacent to tumors (eg, vasogenic edema), likely 
provide information that is not readily available from conventional MRI (19). DTI and fiber 
tractography are new DWI methods that can demonstrate the orientation and integrity of 
white matter fibers in vivo. Although they remain investigational at this time, both DTI and 
fiber tractography show much promise in assessing the integrity of white mater tracts and 
promise to provide much needed information for preoperative planning for brain tumors in 
and around eloquent white matter tracts (18,20,21). 
 
MRS allows a non-invasive qualitative and quantitative analysis of a number of metabolites 
within the brain (22). Recent advances have been made through the use of multivoxel 
techniques and metabolite maps, which allow assessment of both the entire volume of the 
lesion and the surrounding normal-appearing brain tissue. Recent studies suggest the utility 
of this technique in making a specific diagnosis, determination of histologic grade, guiding 
biopsies, therapeutic planning, and to monitor patients after treatment (22,23). 
 
Perfusion MRI can be used to evaluate hemodynamic properties of the tumor such as tumor 
blood volume or blood flow, oxygenation, vessel size, and vascular permeability (5). 
 
Advanced MRI techniques have already become indispensable to the neurosurgeon. Brain 
tumor clinical review boards cannot function without extensive discussion of perfusion and 
spectroscopic data. Preoperative knowledge is intra-operative power for the neurosurgeon. 
That power will only grow with the evolution of advanced MRI techniques (24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
Figure 1. Histopathological appearance of astrocytic tumors.a Astrocytoma WHO 
grade II: a tumor composed of uniform astrocytic, light atypical cells embedded in a 
microcystic stroma (40 x HPF). b Anaplastic astrocytoma WHO grade III: a tumor with 
high cellularity composed of cells with nuclear pleomorphism and mitotic activity (40 
x HPF). c, d Glioblastoma WHO grade IV: a tumor with high cellularity composed of 
mitotically active atypical cells (40 x HPF) (c), and vascular proliferation, thrombosis 
(not shown) and necrosis present (20 x HPF) (d). (Courtesy of Dr. Kumar, Oslo 
University Hospital). 
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Minds behind the history of Nuclear Magnetic Resonance and Magnetic 
Resonance Imaging. 
 
“We cannot clearly be aware of what we possess till we have the means of knowing what others possessed 
before us. We cannot really and honestly rejoice in the advantages of our own time if we know not how to 
appreciate the advantages of former periods” (25). 
Johan Wolfgang von Goethe, 1810 
 
Microscopic imaging of the nervous system was pioneered by Camillo Golgi who discovered 
the reazione nera (black reaction) and Santiago Ramón y Cajal, who made countless 
contributions to the neurosciences, and formulated the four principles that make up the 
neuron doctrine: the neuron, the synapse, the connection specificity and the dynamic 
polarization. The neuron doctrine constitutes the cornerstone on which, throughout the 20th 
century, all the neuroscientific disciplines were constructed. For his revolutionary insights, 
Cajal received the Nobel prize in Physiology or Medicine in 1906, together with Golgi, whose 
silver stain made Cajal`s discoveries possible (26,27,28,29). 
 
Medical imaging began in Würtzburg, Bavaria, on November 8, 1895, when Wilhelm Conrad 
Röntgen detected a new form of radiation coming from a cathode ray tube he was studying 
(30). Clinically useful X-rays images were produced almost immediately. He was awarded the 
Nobel Prize for Physics in 1901. Neuroradiology began in the early 1900s with the use of skull 
radiographs to evaluate brain tumors and other lesions by Arthur Schüller. Schüller who was 
the first to use the term “Neuro-Röntgenologie”, and to call attention to displacement of the 
pineal gland by cerebral tumors (31). This was followed by the development of 
ventriculography in 1918, pneumoencephalography in 1919 by Walter E. Dandy, 
arteriography in 1927 by Egas Moniz (32), and the contributions of the Swedish school of 
neuroradiology. Perhaps the greatest advance in cerebral angiography was the introduction 
by Seldinger, of the catheter to replace the needle (33). Amundsen of Norway was the first 
to catheterize and examine routinely all cerebral vessels, carotis as well as vertebral arteries, 
via the femoral route, a technique he has been using at the Department of Neuroradiology, 
Ullevål University Hospital in Oslo (my alma matter) since 1964 (34). Moniz´s method was 
probably the most accurate of the 3 techniques mentioned above for localizing intracranial 
lesions. Neuroradiology was forever changed when computed tomography (CT) was 
introduced in the 1970s because the brain structure became visible. A paradigm shift 
happened with the advent of MRI, a decade after CT (35). The remarkable and fascinating 
history of nuclear magnetic resonance (NMR) and MRI is presented here through the 
investigators that made it possible (Figure 2). 
 
Isidor Isaac Rabi 
 
Isidoor Isaac Rabi was born in Rymanow, Galicia, in what was the Austria-Hungary, on July 
29, 1898. In 1927 he received his Ph.D. degree for work on the magnetic properties of 
crystals. Aided by fellowships, he spent two years in Europe to experience physics at the 
cutting edge, working at different times with Sommerfeld, Bohr, Pauli, Stern, and 
Heisenberg. In 1930, he began studying the magnetic properties of atomic nuclei, developing 
Stern`s molecular beam method to great precision, as a tool for measuring these properties. 
This apparatus was based on the production of ordinary electromagnetic oscillations of the 
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same frequency as that of the Larmor precession of atomic systems in a magnetic field. By 
an ingenious application of the resonance principle he succeeded in detecting and 
measuring single states of rotation of atoms and molecules, and in determining the 
mechanical and magnetic moments of the nuclei (36,37,38). This led to the publication of  “A 
new method of measuring nuclear magnetic moment” in 1938 where the first MR signal 
from LiCL (lithium chloride) was reported (39). He was awarded the Nobel Prize in Physics 
1944 “for his resonance method for recording the magnetic properties of atomic nuclei”. A 
few months before Rabi died in the early 1980s, his doctors watched as he was gently moved 
into the bore of a MRI machine. Once inside the machine, Rabi saw a distorted image of his 
face in the cylindrical surface surrounding him “it was eerie”, Rabi said “I saw myself in that 
machine. I never thought my work would come to this”. 
 
Edward Mills Purcell and Felix Bloch  
 
E.M. Purcell was born in Taylorville, Illinois, U.S.A., on August 30, 1911. He graduated from 
Purdue University in Indiana in electrical engineering in 1933. He spent one year at the 
Technische Hochschule, Karlsruhe, Germany, where he studied under professor W.Weizel. 
He returned to the United States in 1934 to enter Harvard University, where he received the 
Ph.D. degree in 1938 (37,38). 
 
F.Bloch was born in Zurich, Switzerland, on October 23, 1905. He studied physics at the 
Federal Institute of Technology in Zurich. He continued his studies with Heisenberg at the 
University of Leipzig, where he received his degree of Doctor of Phylosophy in the summer 
of 1928 with a dissertation dealing with the quantum mechanics of electrons in crystals and 
developing the theory of metallic conduction. Upon Hitler`s ascent to power, Bloch left 
Germany in the spring of 1933, and a year later he accepted a position which was offered to 
him at Stanford University (37,38). 
 
At the end of the war, in 1946, Purcell, Torrey, and Paul published a report in Physical 
Review on NMR effects in solids (40). At the same time, Bloch, Hansen, and Packard made a 
similar and successful attempt to measure what they called “nuclear induction” (41). These 
reports were crucial for modern applications of NMR in solution and human tissue because 
they transferred knowledge about Rabi`s work in molecular beams into an effect that had 
been observed in bulk matter (36). Bloch and Purcell were awarded the 1952 Nobel Prize in 
Physics “for their development of new methods for nuclear magnetic precision 
measurements and discoveries in connection therewith”.  
 
Richard R. Ernst 
 
R.R. Ernst was born in 1933 in Winterthur, Switzerland. Ernst received both his diploma in 
chemistry (1957) and his Ph.D. in physical chemistry (1962) from the Federal Institute of 
Technology in Zurich. From 1963 to 1968 he worked as a research chemist in Palo Alto, 
California. In 1968, he returned to Switzerland to teach at his alma matter (38). Ernst and 
Anderson introduced Fourier techniques into NMR (36). The paper that described these 
achievements was rejected twice by the Journal of Chemical Physics to be finally accepted 
and published in the Review of Scientific Instruments (42). After an oral presentation by Jean 
Jeenes, Ernst developed two-dimensional (2D) NMR spectroscopy, which is also the basis for 
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modern imaging techniques in medicine. Ernst was awarded the 1991 Nobel Prize in 
Chemistry “for his contributions to the development of the methodology of high resolution 
nuclear magnetic resonance spectroscopy”. In his Nobel Lecture, R.R. Ernst revealed an 
astonishing fact: quite a few scientists who contributed to the early development of NMR 
received a Nobel prize in Physics for their subsequent work in other areas. A.Kastler (Nobel 
laurate 1966) was one of those who proposed the “double resonance method”, combining 
optical with magnetic resonance. J.H.Van Vleck (Nobel laureate 1977) developed the theory 
of dia-and paramagnetism. Nicolaas Bloembergen (Nobel laureate 1981) worked in reflux 
atom effects and the influence of motion. H.A. Miller (Nobel laureate 1987) contributed 
significantly to electron paramagnetic resonance. H.G. Dehmelt (Nobel laureate 1989) 
developed paranuclear quadruple resonance. N.F. Ramsay (Nobel laurate 1989) was 
I.I.Rabi`s first graduate student and introduced the concept of the chemical shift and J 
coupling (36). 
 
Kurt Wüthrich 
 
K.Wüthrich was born in Aarberg, Switzerland, on October 4, 1938. K. Wüthrich was educated 
in chemistry, physics, and mathematics at the University of Berne (38). He and his group 
applied NMR techniques for the evaluation of three-dimensional (3D) structures of biologic 
macromolecules (36). He was awarded the Nobel Prize in Chemistry in 2002 “for his 
development of nuclear magnetic resonance spectroscopy for determining the three-
dimensional structure of biological macromolecules in solution”. 
 
Paul C. Lauterbur 
 
P.C.Lauterbur was born in Sidney, Ohio, U.S.A., on May 6, 1929. MRI was first demonstrated 
on two small tubes of water by Lauterbur, who used a back projection technique similar to 
that of CT (38). Lauterbur published his work in Nature in an article entitled “Image 
formation by induced local interaction; examples emplying magnetic resonance” (43). When 
Lauterbur first submitted his paper with his discoveries to Nature, the paper was rejected by 
the editors of the journal. Lauterbur persisted and requested them to review it again, upon 
which time it was published and is now acknowledged as a classic Nature paper. The Nature 
editors pointed out that pictures accompanying the paper was too fusy, although they were 
the first images to show difference between heavy water and ordinary water. Lauterbur said 
of the initial rejection ” you could write the entire history of science in the last 50 years in 
terms of papers rejected by Science or Nature” (37, 38). There is no question that 
Lauterbur`s 1973 publication in Nature represents a milestone in the development of MR in 
Medicine. He suggested that magnetic field gradients could be used to define the spatial 
distribution of protons in water by different frequencies (36). By analysis of the 
characteristics of the emitted radio waves, he could determine their origin. This made it 
possible to build up 2D pictures of structures that could not be visualized with other 
methods. This imaging experiment, therefore, moved from the single dimensions of MRS to 
the second dimension of spatial orientation and this became the foundation of MRI (37). 
Lauterbur shared the 2003 Nobel Prize in Physiology or Medicine with Peter Mansfield 
(discussed below) “for their discoveries concerning magnetic resonance imaging”. 
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Peter Mansfield 
 
Peter Mansfield was born 9th October 1923 in Lambeth, London. He studied physics at 
Queen Mary College, London, graduating with a Bsc in 1959 and a Ph.D. in 1962 (38). The 
contributions of Mansfield and the Nottingham group are numerous and fundamental. They 
include: NMR diffraction in solids, slice selection, active magnetic shielding of gradient coils 
echo volume imaging, active acoustic shielding methods that lower noise levels produced by 
gradient coils. Of great relevance to the field of fast MRI, and in particular to diffusion, 
perfusion and functional imaging of the brain (37). Mansfield further developed the 
utilization of gradient magnetic fields. He showed how the signals can be mathematically 
analyzed which later gave rise to the echo-planar imaging (EPI) technique in 1977 (44). 
Furthermore, Mansfield was the first to demonstrate clinical MR images using this 
technique. Thus, modern MRI of human internal organs with exact and non-invasive 
methods was born (37). For this reason, he was awarded the 2003 Nobel Prize in Physiology 
or Medicine (shared with Lauterbur) for his discoveries concerning magnetic resonance 
imaging. 
 
In 2001 a group of 225 physicians were surveyed and selected MRI, along with CT, as the 
most important medical innovation in terms of advancing patient care in the previous 25 
years. In conclusion, MR continues to thrive on innovation and to broaden its scope, 
apparently without limit. The foundation laid down by the contributions of the scientists 
mentioned above, however, still remains (35). Table 1 lists Nobel Prizes for NMR (36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 INTRODUCTION 
 
 
 
 
Table 1. Nobel Prizes directly related to NMR and MRI. 
 
Name Year Field Prize motivation  
 
Country 
Isidor Isaac Rabi 1944 Physics For his resonance method for recording the magnetic properties of atomic 
nuclei 
USA 
Edward Mills 
Purcell 
1952 Physics For their development of new methods for nuclear magnetic precision 
measurements and discoveries in connection therewith 
USA 
Felix Bloch 1952 Physics For their development of new methods for nuclear magnetic precision 
measurements and discoveries in connection therewith
Switzerland 
Richard R. Ernst 1991 Chemistry For his contributions to the development of the methodology of high 
resolution nuclear magnetic resonance spectroscopy 
Switzerland 
Kurt Wüthrich 2002 Chemistry For his development of nuclear magnetic resonance spectroscopy for 
determining the three-dimensional structure of biological macromolecules in 
solution 
Switzerland 
Peter Mansfield 2003 Medicine For their discoveries concerning magnetic resonance imaging UK 
Paul C. Lauterbur 2003 Medicine For their discoveries concerning magnetic resonance imaging USA 
Modified from (36).  
 
          
Isidor Isaac Rabi                   Felix Bloch                         Edward Mills Purcell Richard R. Ernst                    
Nobel Prize in Physics         Nobel Prize in Physics     Nobel Prize in Physics Nobel Prize in Chemistry    
1944                                       1952                                   1952   1991 
 
         
Kurt Wüthrich                         Paul C. Lauterbur                    Sir Peter Mansfield 
Nobel Prize in Chemistry        Nobel Prize in Medicine          Nobel Prize in Medicine  
 2002                                          2003                                           2003 
 
 
Figure 2. Nobel Prizes directly related to NMR and MRI (Photos: Scanpix). 
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Clinical MR Neurospectroscopy 
 
MRS provides a means to characterize the metabolite profiles of tumoral and non-tumoral 
lesions in the brain (23). 
 
Neurochemistry in MRS 
 
Figures 3 and 4 show examples of proton spectra recorded at short and intermediate echo 
time (TE). The assignment and significance of each the resonances in the spectrum is 
discussed below. 
 
N-acetyl aspartate 
 
The largest signal in the normal adult brain spectrum, the N-acetyl group of N-acetyl 
aspartate (NAA) resonates at 2.01 ppm, with a smaller contribution from N-acetylaspartyl 
glutamate (NAAG) at 2.04 ppm, particularly in white matter (45,46). NAA is believed to be 
synthesized in neuronal mitochondria, from aspartate and acetyl-CoA. NAA is often referred 
to as a neuronal marker, based on several lines of evidence. Using immunocytochemical 
technique, NAA has been shown to be predominantly localized to neurons, axons and 
dendrites within the CNS (47,48), and studies of diseases known to involve neuronal and/or 
axonal loss (infarcts, brain tumors, multiple sclerosis plaques, for example) have without 
exception found NAA to be decreased (45,47). However, some experiments suggest that 
caution should be used in interpreting NAA solely as a neuronal marker. For instance, it has 
also been reported that NAA may be found in non-neuronal cells, such as mast cells or 
isolated oligodendrocyte preparations, suggesting that NAA may not be specific for neuronal 
processes (45,49). NAA does appear to be one of the better surrogate neuronal markers 
currently available for neuronal integrity in many neurological and psychiatric disorders. 
Decreases in NAA in some diseases have been shown to be reversible, suggesting that low 
NAA does not always indicate permanent neuronal damage (45,50). Reversible NAA deficits 
(either spontaneous, or in response to treatment) have been observed in diseases such as 
multiple sclerosis, mitochondrial diseases, AIDS, temporal lobe epilepsy, amyotrophic lateral 
sclerosis, or acute disseminated encephalomyelitis. However, in certain types of lesion (e.g., 
chronic infarction, brain tumors), it appears likely that reduction in NAA does indeed 
correspond to irreversible neuronal loss (45, 47). In brain tumors, the decrease in NAA 
represents the replacement of normal functioning neurons and axons with neoplastic tissue 
(23). 
 
Choline 
 
The choline (Cho) signal occurs at 3.24 ppm, and is a composite peak consisting of 
contributions from the N (CH3)3 groups of glycerophosphocholine (GPC), phosphocholine 
(PC), and a small amount of free Cho (47). These compounds are involved in membrane 
synthesis and degradation, and it has often been suggested that they are elevated in disease 
states where increased membrane turnover is involved (e.g., tumors). Elevated Cho levels 
seem to be a characteristic of many types of neoplasms, including high-grade brain tumors, 
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prostate, breast, head and neck, and others (45,47). Measurables levels of Cho vary 
considerably, depending on the cellular density, tumor grade and presence or absence of 
necrosis (23). Cho resonance is most prominent in regions with high neoplastic cellular 
density and is progressively lower in moderate and low-grade tumors (50,51). Paradoxically, 
some highly malignant tumors and some GBM may show low Cho because of extensive 
necrosis (51,52). 
  
Creatine 
 
The creatine methyl resonance (Cr) observed at 3.03 ppm is a composite of both Cr and 
phosphocreatine (PCr), compounds that are involved in energy metabolism via the creatine 
kinase reaction, generating adenosine triphosphate (ATP) (45). An additional peak for Cr is 
visible at 3.91 ppm. Before Cr can be available for transport to the brain, it must be 
synthesized. The absolute cerebral Cr concentration falls in chronic liver disease. Even more 
striking is the discovery of a new human inborn error of Cr biosynthesis, that is manifested 
as absence of cerebral Cr from spectrum (53). Reduction in total Cr below normal levels has 
been reported as a feature of HGGs (54), metastases (54), and meningiomas (55). 
 
Lactate 
 
In normal human brain, lactate (Lac) observed at 1.33 ppm is usually below the limit of 
detectability in most in vivo MRS studies (47). Lac has a configuration consisting of two 
closely spaced resonant peaks called a “doublet”. This is caused by magnetic field interaction 
between adjacent protons (J-coupling). Altering echo time (TE) may provide confirmation 
that a peak at 1.32 ppm is Lac. At TE=272 milisecond (ms) Lac projects above the baseline, 
while at TE=136 ms Lac is inverted below the baseline (56). Lac is thought to be an indicator 
of altered metabolism in brain tumors. Lac levels in brain tumors reflect the availability of 
glucose as well as the oxygenation status (57). High-grade tumors such as GBM and 
metastases often exhibit observable Lac resonances (54). 
 
Myo-inositol 
 
Myo-inositol (MI) observed at 3.5-3.6 ppm, is a pentose sugar, which is part of the inositol 
triphosphate intracellular second messenger system (45). MI resonates at almost the same 
frequency in the spectrum as glycine; however, glycine is a singlet, while MI is a strongly 
coupled multiplet, so the two can usually be distinguished by using different echo times (45). 
MI is typically increased in glial tumors relative to normal brain (58) and is generally higher in 
LGGs than HGGs or metastases (59). 
 
Glutamate and glutamine 
 
Glutamate (Glu) and glutamine (Glm) are key components in brain metabolism. Glu is the 
most abundant amino acid in the brain, and is the dominant neurotransmitter (60). Glu and 
Glm are difficult to separate in proton spectra at 1.5 T, and they are usually labeled as a 
composite peak “Glx”, at 2.1 to 2.5 ppm (45,47). 
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Lipid 
 
Lipids (Lip) observed at 0.9 ppm and 1.3 ppm are found normally within cell walls and usually 
not evident on normal spectra. When evident, they are generally thought to be related to 
cellular membrane breakdown (61). Lip resonances are typically elevated in high-grade 
astrocytomas and metastases (57). 
 
Practical considerations 
 
Spatial localization: Single versus multivoxel MRS 
 
Different spectroscopic techniques are available. Single-voxel spectroscopy (SVS) was mainly 
used in the past because of its wide availability and simplicity (22). SVS samples a smaller 
volume of tissue and is useful in analyzing generalized disease where location of the voxel is 
not critical, but compromises on the area examined (23). One limitation is the lack of ability 
to determine spectral heterogeneity of spectral patterns (often very important in brain 
tumors, for instance), and the fact that only a small number of brain regions can be covered 
within the time constraints of a normal clinical MR exam (45). 
 
Multi-voxel spectroscopy, called chemical shift imaging (CSI) or magnetic resonance 
spectroscopic imaging (MRSI), either 2D or 3D, obtains spectroscopic information from 
multiple adjacent volumes over a large volume of interest (VOI) in a single measurement 
(22,23). These techniques can measure multiple areas of the brain within acceptable 
acquisition times. MRSI can be combined with conventional MRI, since spectral patterns and 
metabolite concentrations can be over-load on gray-scale imaging to compare voxels 
containing normal parenchyma and voxels containing pathology and also to obtain 
distributional patterns of specific metabolites (24,62). Furthermore, the relative 
concentration of metabolite in the selected volume can be graphically displayed with a color 
scale and superimposed on the conventional images (22). A valuable addition to the reading 
of CSI, termed “voxel shifting”, can be performed at any time after the examination is 
completed. In this procedure, the reader at a workstation can determine which structure or 
structures need to be separated from adjacent brain, and then shift the grid so that one or 
more voxels fit precisely over the desired lesion (63). MRSI has some limitations. The VOI 
must be positioned so that it includes both tumor and normal tissue without inclusion of 
unwanted structures (e.g., lipid-containing structures) that may degrade the spectrum 
quality (22). Such contamination can be eliminated by carefully placing outer volume 
saturation slabs outside the VOI. It is generally agreed that 3D MRSI provides the most 
comprehensive spectroscopic assessment of brain tumors.  
 
Pulse sequences and protocol design: PRESS versus STEAM, short versus long TE 
 
The type of the MR signal recorded (free induction decay [FID]; spin echo (SE), or stimulated 
echo) is determined by the choice of the MRSI localization sequence. Point resolved surface 
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coil spectroscopy (PRESS) and stimulated emission acquisition mode (STEAM) are the most 
commonly used in proton MRS studies (64). 
 
Proton MRS performed with long echo time (TE 270 to 288 ms), intermediate echo time (TE 
135 to 144 ms) or short echo (TE 20 to 40 ms) allows the identification and quantitation of 
important cerebral metabolites. Short TE is useful in demonstrating MI, Glx and Lip. These 
metabolites are becoming important in the characterization of tumors and monitoring 
therapy. Intermediate TE is useful in differentiating Lac and alanine from lipids around 
1.3/1.4 ppm by J-modulation/inversion of the Lac and alanine doublets. The intermediate TE 
allows more reproducibility and accuracy, particularly for quantification of Cho and NAA 
peaks, major peaks in tumor characterization. At longer TE due to the T2 decay of 
metabolites, there is less signal from NAA, Cho and Cr relative to the baseline noise and 
hence the signal to noise is lower than short and intermediate TE measurements (23). 
 
MRS and magnetic field strength 
 
MRS is one of the MR techniques that profits from higher magnetic field strength in more 
than one way. The signal-to-noise ratio (SNR) at 3.0 T is more than welcome to enable higher 
spectral quality, higher spectral resolution, or fast MRSI. Higher order shimming is essential if 
full advantage is to be taken from the increased SNR and spectral dispersion. Furthermore, 
radio frequency (RF) pulses or localization sequences have to be adapted to overcome 
metabolite misregistration or ever signal loss problems (65).  
 
Pre versus post-contrast MRS 
 
Most recent studies showed no significant change of spectrum quality after contrast 
material administration (66,67). In normal brain, gadolinium (Gd) stays within the 
vasculature, so its only effect on metabolites is to cause a slight line broadening at typical, 
steady-state concentrations. Even in enhancing brain lesion, Gd is most likely in the 
extravascular, extracellular space, and does not appear to cause significant changes in 
metabolite T1 and T2 relaxation, since most metabolites are within the intracellular space 
(45). For the evaluation of brain tumors, it is often recommended that MRS be performed 
after contrast-enhanced T1-weighted imaging to better define the various components of 
the lesion and to position the VOI with accuracy (22,66,67). 
 
MRS of brain tumors 
 
Assessment of glioma grade 
 
It has been found that nearly all brain tumors have decreased NAA signals, and often have 
increased levels of Cho, leading to increase Cho/NAA ratio (68). Other relatively common 
metabolic changes in brain tumors are elevated signals in the Lac and Lip region of the 
spectrum (68), and sometimes increased levels of MI in short TE spectrum (69). Lac peak is 
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mainly observed in cases of HGGs, and an elevated level of MI is suggestive of LGGs (70). The 
observation of elevated Lip levels is believed to be associated with necrosis and membrane 
breakdown (57,71), and has also been shown to be useful in differentiating HGGs from LGGs 
(23,57). Cho levels is found to be higher in HGGs than in LGGs (22). This would appear 
consistent with the more aggressive tumors having higher membrane turnover and cellular 
density (68). However, some studies have found high-grade tumors (GBM) to have lower 
levels of Cho than grade II or III astrocytoma (57). This may be due to the presence of 
necrosis in high-grade tumors, because necrosis is associated with low levels of all 
metabolites (72). Law et al. (73) demonstrated a threshold value of 1.56 for Cho/Cr to 
provide sensitivity, specificity, positive predictive (PPV) and negative predictive values (NPV) 
of 75.8%, 47.5%, 81.2% and 39.6% respectively for the determination of a HGG versus LGG. 
Representative case of HGG is shown in figure 5. 
 
Metastatic neoplasms 
 
Solitary brain metastases may be indistinguishable from primary glioma by conventional 
MRI. The intratumoral MRS is also not able to reliably differentiate between the metastases 
and glioma (23). Ishmaru et al. (74) showed that the absence of intratumoral Cr peak was 
suggestive of metastasis. In addition, the authors noticed that the absence of Lip signal of a 
TE of 30 ms could exclude the diagnosis of metastases. However, in areas of central necrosis 
in HGGs, there is also often Lip and Lac, as well as a lack of Cr, so the intratumoral spectrum 
is often non-specific (23). 
For discriminating solitary metastases from primary brain tumors, it has been suggested that 
investigation of perienhancing tumor regions may be useful. Whereas gliomas are often 
invasive lesions that show elevated Cho in surrounding tissue, metastatic lesions tend to be 
more encapsulated and do not typically show high Cho signals or other abnormalities 
outside the region of enhancement (75). 
 
Other applications of MRS in Neuro-oncology 
 
Biopsy guiding 
Recent studies showed that the position of biopsy targets maybe defined according to the 
active portions of the tumor seen on MRSI (76). In one study, metabolic information 
obtained from MRSI was concordant with pathologic findings. Specimens from areas with 
increased choline-to-creatine ratios showed hypercellularity, mitosis, and cellular atypism, 
and areas of increased Lac signal showed tumor necrosis (77). In conclusion, the role of MRS 
in biopsy guidance is to recognize regions of high metabolic activity: regions of elevated Cho 
levels and low NAA levels indicative of tumor tissue, represent a good target for biopsy 
(78,79). 
 
Treatment planning 
 MRSI provides information on tumor heterogeneity, including distinguishing normal tissue, 
infiltrating tumor, and vasogenic edema (80). This information is of great potential value in 
planning targeted radiotherapy. 
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MRS in radiation injury and response to treatment 
Sundgren et al. (81) in a study of 11 patients with primary brain tumors that underwent 
cranial radiation therapy, showed that MRS can detect early metabolic changes in normal 
irradiated brain tissue. In a recent report, the authors demonstrated a correlation between 
an elevated Cho/NAA ratio and evidence of tumor recurrence in patients with radiation-
treated primary brain tumors who present with new contrast-enhancing lesions on 
conventional MRI follow-up (82). In a recent review article by Sundgren, the role of MRS to 
distinguish recurrent tumor from radiation necrosis or radiation injury is discussed (83). 
 
Special considerations and challenges about grading of gliomas and the 
differential diagnosis between high-grade gliomas and metastases 
 
First, the clinical utility of tumoral MRS in glioma grading is still being investigated. At this 
point, it is important to understand that MRS is very sensitive to abnormal metabolic 
changes but the specificity is relatively low (84). Clinically it is not uncommon to find some 
LGGs with very high Cho/Cr and Cho/NAA ratios and conversely HGGs, with lower Cho/Cr 
and Cho/NAA ratios due primarily to extensive necrosis which increases false positive and 
false negative rates respectively. There is some overlap in Cho/NAA statistical index (CNI) 
between tumor of different grades (85). This is the reason that further studies are required. 
 
Second, a number of studies have examined tumor grading but did not report diagnostic 
performance measurements such as, sensitivity, specificity, or area under the curve (AUC) 
estimates (86). 
 
Third, the ability of MRS to differentiate gliomas from metastases remains controversial 
(22,87,88). The differences in the neurochemistry of the peritumoral region of gliomas and 
metastases results in differences in Cho, which can differentiate between these two 
pathologies (23). Further studies are required to evaluate the diagnostic accuracy of MRS, in 
particular, in the peri-enhancing region. 
 
Fourth, MRS has not been widely accepted as a routine clinical tool. MRS is only relatively 
occasionally used for tumor evaluation outside of major academic medical centers (68). 
Further studies are required to advance knowledge, validate hypothesis, and to evaluate its 
diagnostic accuracy and whether it can positively affect diagnostic thinking and therapeutic 
choice. 
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Figure 3. Single-voxel proton MRS of the normal-
appearing brain tissue shows normal metabolite 
levels at echo time (TE) 30 ms. 
                    
 
Figure 4. Single-voxel proton MRS of the normal-
appearing brain shows normal metabolite levels at 
echo time (TE) 135 ms. 
Figure 5. Spectrum from a high-grade glioma (not 
shown) at echo time (TE) 135 ms demonstrating 
increased Choline (Cho) and decreased N-acetyl 
aspartate ( NAA) and Creatine (Cr). 
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Perfusion and permeability MRI 
 
In brain tumors, perfusion MRI proposes to measure the degree of tumor angiogenesis and 
capillary permeability, both of which are important biologic markers of malignancy, grading, 
and prognosis, particularly in gliomas (89). 
 
Imaging techniques 
 
The 4 major techniques currently used in both the clinical and research settings are: 1) T1-
weighted steady-state dynamic contrast-enhanced MRI (DCE MRI) method, 2) T2*-weighted 
first-pass, dynamic susceptibility contrast-enhanced perfusion MRI (DSC MRI) method, 3) 
arterial spin labeling (ASL) method; and 4) vascular space occupancy (VASO) imaging (13,90). 
The following sections focus on the DSC MRI method, because it is the method we have used 
to study and quantify brain tumors vasculature in this thesis (Papers IV,V). 
 
DSC MRI 
 
In DSC MRI, the signal measured is due to the susceptibility T2 or T2* effect induced by the 
injected contrast agent (13). The most robust and widely used quantitative variable derived 
from DSC MRI is the relative cerebral blood volume (rCBV) (89). The theory of nondiffusible 
traces kinetics can be used to derive CBV values from the concentration-time curves. On 
injection of a contrast agent (gadopentetate dimeglumine), a signal intensity versus tissue 
curve is obtained. CBV is proportional to the area under the contrast agent concentration, 
signal intensity-time curve, in the absence of recirculation and contrast leakage (13). From 
the susceptibility signal intensity-curve, gadopentetate dimeglumine, which is proportional 
to the change in relaxation rate ([R2*] ie, the change in the reciprocal of T2*), can be 
calculated from the signal intensity by using the following equation (91): 
 
R2* = [-ln(SIt/SI0)/TE]                         [1] 
 
where SIt is the pixel signal intensity at time t, SI0 is the precontrast signal intensity, and TE is 
the echo time (91). This equation is only valid if T1 enhancement associated with blood-brain 
barrier (BBB) disruption has a negligible effect on signal intensity (13,89). 
 
Sequence consideration: Spin-echo versus gradient-echo DSC MRI 
 
The presence of Gd through the microvasculature results in changes in both T2 and T2* so 
that both spin-echo (SE) and gradient-echo (GRE) sequences will provide reliable and 
reproducible CBV measurements (13). 
 
The advantages of using SE sequences include less susceptibility to artefacts, particularly 
near the skull base or at brain-bone-air interfaces, and the increased sensitivity to SE 
perfusion to contrast within the capillaries (13,92). It has been demonstrated that SE 
sequences are mainly sensitive to smaller vessels (<20 m) and hence may provide more 
optimal imaging of tumor capillaries. However, GRE sequences seem to be sensitive to both 
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capillary and larger-vessel perfusion (13,93). Combined SE and GRE techniques can be 
performed (13,94), and this combination can also be used to determine vascular diameter or 
size, which is important when monitoring antiangiogenic therapy (95). Furthermore, 
Schmainda et al. (94) have reported that significant correlation was found between GRE 
rCBV and tumor grade. 
 
Technical considerations 
 
DSC MRI is the most commonly used and easily applied technique for studying brain tumor 
perfusion. There are, however, several significant issues that should be appreciated. First, 
because the technique is weighted to measure susceptibility, it is extremily sensitive to 
structures of lesions that cause magnetic field inhomogeneity such as blood products, 
calcium, bone, melanin, metals, or lesions near the brain-bone-air interface, such as the skull 
base. Solutions to reduce the inhomogeneity and susceptibility include decreasing the slice 
thickness and parallel imaging methods (13). Second, T2*-weighted acquisitions commonly 
have significant T1 sensitivity, such that any contrast leakage produces artifactual elevations 
in the signal time course curve (90,96,97). This is particularly problematic in tumors where 
BBB breakdown has occurred. Acquisitions must, therefore, be designed to minimize the T1 
effect. The most common solution is the use of low flip angle GRE sequences (90,96). 
Leakage correction can also be applied to minimize susceptibility effects by preload-
correction and dual acquisition approach (98), or combining preload dosing (PLD) and 
baseline substraction (BLS) (99). Alternative method has been described by Boxerman (100), 
by using a linear fitting algorithm that allows generation of both corrected rCBV maps and 
first-order estimates of vascular permeability. 
 
Clinical applications of perfusion MRI 
 
Perfusion MRI can be used to evaluate hemodynamic properties of the tumor such as tumor 
blood volume or flow, oxygenation, vessel size, and vascular permeability (5). A generic 
advantage of perfusion and permeability imaging is that they both incorporate microvascular 
information (101). 
 
Distinction of glioma tumor grade 
 
In primary HGGs, vascular morphology is a critical parameter in determining malignancy 
potential and survival and glioma grading is important for determining both prognosis and 
therapy (89). Several studies suggest that MRI-derived rCBV may better differentiate 
histologic tumor types than conventional MRI and provide information to predict glial tumor 
grade (102). Low-grade astrocytomas have a significantly lower average rCBV than anaplastic 
astrocytomas (AA) or GBM (103). However, there are nonastrocytic gliomas that have high 
rCBV even in low-grade tumors. Oligodendrogliomas demonstrate elevated rCBV, even in 
low-grade tumors, that can be as high as the GBM (104). In some institutions, rCBV maps are 
routinely used to select biopsy sites for both enhancing and nonenhancing tumors and help 
reduce sampling error and nondiagnostic biopsies (18). Example of GBM is given in Figure 6. 
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Differentiating primary and secondary brain tumors 
 
Metastatic brain tumors usually do not pose a diagnostic dilemma on MRI, because they 
tend to be multiple, and often a known histology of systemic malignancy is present (89). 
Approximately, 30% or more of metastatic brain tumors, however, can manifest as a single 
lesion in the brain and, in some cases, as the initial clinical presentation of systemic 
malignancy (105). In one study, investigators using DSC methods to study tumor margins 
found that rCBV values in the peritumoral regions of HGGs were significantly higher than in 
metastases (75). However, in the same study, rCBV in metastases was substantially higher 
than in gliomas, which seems at variance with the findings of higher rCBV in peritumoral 
regions of HGGs. Another study also found significantly higher rCBV values in the 
peritumoral regions of HGGs than in metastases; in that study, rCBV values in the two types 
of tumors being studied were very similar (106). 
 
Other applications of perfusion MRI 
 
The biomarkers of microvascular structure and function are increasingly demonstrating 
clinical potential in a variety of roles (90), such as: differentiating abscess and tumor (107), 
differentiating lymphoma and glioma (108,109), differentiating tumefactive demyelinating 
lesions from intracranial neoplasms (93), predicting transformation of LGG (110,111), 
predicting therapeutic respons and prognosis in HGGs (112), and in distinguishing tumor 
recurrence and radiation necrosis (113). 
 
Special considerations and challenges about predicting of gliomas, and 
assessment of peritumoral regions by using DSC MRI 
 
The major limitations in interpreting studies of new MRI techniques in gliomas are the small 
number of patients involved and the lack of confirmatory imaging trials (5). There remain 
significant challenges to be overcome before the techniques and related biomarkers can find 
their transition into routine clinical practice. 
 
First, there are few reports in the literature describing the false-positive and false-negative 
rates for glioma grading and in differentiating primary and secondary brain tumors using 
rCBV, and in particular with rCBF and degree of permeability. Defining the role of these 
biomarkers in clinical practice, in terms of measures of diagnostic examination performance, 
and determining whether rCBV, rCBF, permeability or the combination of these biomarkers 
needs further investigation. 
 
Second, there is a complicated relationship between rCBV and rCBF (5). Measurement of CBF 
provides information not derived from CBV measurements. Further studies are required to 
evaluate CBF measured from DSC MRI and to assess the correlation between these 
microvascular imaging biomarkes (rCBV, rCBF and microvascular leakage). 
 
Third, although investigators have been heavily reliant on DSE techniques to determine 
degree of permeability within tumors, permeability can be assessed from DSC MRI (102). 
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Further studies are required to estimate the correlation between degree of permeability and 
tumor grade. 
 
Fourth, another problem that neuroradiologists encounter on a fairly regular basis is the 
definition of tumor margins on cross-sectional imaging studies (102). The role of perfusion 
MRI in the assessment of peritumoral regions in order to evaluate tumor extension beyond 
the regions that contrast enhance on imaging studies both in the grading of gliomas and in 
the distinction of HGGs from metastases require further investigation. 
Finally, it has been demonstrated that inclusion of large intracranial vessels significantly 
increases rCBV values in all types of LGGs (114). There are few reports specifying exclusion of 
large intratumoral vessels for region of interest (ROI) analysis (115) or histogram analysis 
(116). Further studies using automatic vessel segmentation from DSC MRI are required. 
 
 
 
 
Figure 6.  A 70-year-old-man with a histologically verified glioblastoma multiforme in the left frontal lobe. a Axial T1-
weighted image shows a thick and nodular ring-like enhancing mass with central necrosis. Note also the mass effect and the 
surrounding white matter edema. b, c Axial DSC MRI with rCBV (b) and rCBF (c) maps, showing a lesion with high perfusion 
within the tumor. d Axial microvascular leakage color overlayed onto postcontrast T1-weighted image shows markedly 
elevated permeability. 
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Diffusion weighted MRI 
 
Theoretic basis and imaging techniques 
 
Diffusion imaging examines the motion of water molecules, which is normally random or 
Brownian in the unimpeded, isotropic state (117,118,119). The brain has natural barriers to 
the motion of water molecules such as intracellular organelles, macromolecules, and cell 
membrane that result in anisotropic diffusion (117). Given that water moves within and 
across intracellular and extracellular domain, water also encounters impediments presented 
by tortuosity in the extracellular interstitium (118,120). 
 
Sensitivity of the MRI sequence to water mobility is determined by the strength, duration, 
and direction of gradient pulses interleaved within the imaging sequence. The single most 
important parameter selected by the operator for diffusion imaging is the “b-factor”, which 
is calculated based on gradient waveform amplitude and duration properties. As the b-value 
is increased, the signal strength decays because of spin dephasing secondary to random 
molecular displacements (118). 
 
Routine DWI can be used to calculate the ADC, which is a measure of the magnitude of 
water diffusion (117). Transient association of water with large slow-moving 
macromolecules as well as impediment by membranes and other structures effectively 
reduce water mobility to an ADC lower than free water diffusion. The greater the density of 
structures that impade water mobility, the lower the ADC. For this reason, ADC is considered 
a non-invasive indicator of cellularity or cell density (119). 
 
Diffusion tensor imaging (DTI) takes advantage of the preferential diffusion of water in brain 
tissue, which is decreased perpendicular to the myelin sheaths and cell membranes of white 
matter axons (20,121). The diffusion tensor is a mathematical model of water diffusion that 
reflects the anisotropy (directional dependence) and orientation of the local white matter 
fibers (117). Because the tensor is symmetric and represented by a 3 x 3 matrix, at least six 
unique elements are required to characterize it fully (122,123). The tensor can be 
reorganized mathematically or “diagonalized” such that three non-	
1, 2, 3) 
remain along the diagonal. These elements are known as the eigenvalues and represent 
diffusivity along the natural tissue-based axes that may exist in the voxel. The standard 
		
	
1   represent the highest diffusivity value ostensibly along the fiber 
2 	3 are lower values perpendicular to the fiber direction (118,119). 
 
The most common derived DTI metrics are mean diffusivity (MD) and fractional anisotropy 
(FA). MD is the mean of the 3 eigenvalues, or a directionally averaged measure of the 
magnitude of water diffusion. Analogous to the ADC, MD is related to the integrity of the 
brain tissue (117). Anisotropy is usually represented by the FA or, alternatively, the relative 
anisotropy (RA) (119,123). The FA is a measure of the portion of the magnitude of the 
diffusion tensor owing to anisotropy, and the RA is derived from a ratio between the 
anisotropic and isotropic portions of the diffusion tensor (117,119). FA ranges from 0 
(isotropic with zero net direction) to 1 (maximal anisotropy that occurs along the primary 
eigenvector). Other indices available to characterize isotropic and anisotropic elements of 
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) (124,125). In addition to the degree of anisotropy there are geometric 
“shape” indices that may be particularly relevant in tumor that may induce anisotropy by 
compression of otherwise isotropic spherical cells, such as linear (CL), planar (CP) , or 
spherical (CS) tensor shape (117, 126, 127). All these DWI and DTI metrics can be calculated 
with the respective standard algorithms: 
                                                     [2]                             
           [3]
                                                                      [4]
                                                                     [5]
                                                                       [6]
 
Clinical applications of diffusion imaging 
 
MR diffusion imaging has become a widely accepted method to probe the presence of fluid 
pools and molecular tissue water mobility. The measurement of a single diffusion coefficient 
in brain tumors permits an approximate categorization of tumor type and, for some tumors, 
definitive diagnosis (128). 
 
Diffusion imaging in tissue characterization and in tumor grading 
 
In terms of tumors, ADC maps generated from DWI or DTI data have proved helpful in 
defining solid enhancing tumor, non-contrast enhancing lesion, peritumoral edema, and 
necrotic or cystic regions from normal surrounding brain tissue (119). Necrotic regions have 
the highest ADC values (129), whereas contrast enhancing parts of he tumor have lower ADC 
values, presumably due to the presence of tumor cell elements impending mobility (130). 
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Several studies have shown that low-grade astrocytoma has high ADC values, whereas high-
grade malignant glioma has low ADC values, findings reflected more restricted diffusion with 
increasing tumor cellularity (131,132). There remains controversy in the literature on use of 
FA values, however, which are generally reduced in tumors suggesting structural disorders 
may not add much information for tissue classification across tumors (118). One must keep 
in mind the high degree of normal variation in FA depending on location in the brain which 
must be considered and may help explain disparity across studies (118,133). Directionally 
encoded color maps of FA can be categorized into four major patterns of tumor-altered 
white matter tracts: 1) deviated, 2) edematous, 3) infiltrated, and 4) destroyed (134). 
Classification by these patterns may aid presurgical planning and thereby potentially avoid  
damaging an intact tract during surgery (118). Representative case of GBM is shown in 
Figure 7.  
 
Differential diagnosis: Malignant glioma versus metastasis, lymphoma 
 
A low ADC in an intra-axial neoplasm should raise suspicion of lymphoma or metastasis, 
because the higher cellularity of these tumors generally produces an ADC that is significant 
lower than that of glioma (135,136); however, although most gliomas have a much higher 
ADC, a number of case reports and several large series have demonstrated a low ADC in a 
small number of GBM. The resulting overlap among ADC values in the three tumor types 
reinforces the need to integrate DWI with other advanced and conventional neuroimaging 
data for accurate clinical interpretation (137,138). 
 
Peritumoral measurements in malignant gliomas may reveal less marked increases in MD 
than in metastases, and more marked decreases in FA (139), but there are also several 
examples on the contrary (140,141). 
 
 
 
Figure 7. A 62-year-old-woman with a histologically verified glioblastoma multiforme (GBM).a Contrast T1-weighted 
image shows an intraaxial heterogeneously enhancing tumor in the left parietal lobe with necrotic changes, surrounded 
by white matter edema. b Data from the ADC map indicate a mean ADC of 0.95x10-3mm2/sec in the tumor and of 
1.515x10-3mm2/sec in the peritumoral edema at ROIs analysis. c Data from this FA map indicates a mean FA of 0.103 in 
the tumor and of 0.203 in the peritumoral edema at ROIs analysis. d Directionally encoded DTI color map of this 
infiltrating GBM is characterized by both diminished anisotropy and abnormal hues, suggestion disruption of white 
matter fiber tract organization. 
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Other clinical applications of diffusion imaging 
 
Diffusion imaging can provide unique and valuable information with regard to: neurosurgical 
planning (142), treatment response monitoring (117), and in the differentiation of recurrent 
tumor from radiation injury (124). 
 
Challenges of diffusion imaging in the assessment of brain tumors 
 
First, further assessment is needed to verify if DWI can discrimate vasogenic edema from 
tumor-infiltrated edema. 
 
Second, although the ADC is thought to be inversely correlated with tumor cellularity, and 
hence glioma grade, its clinical effect remains limited because of substantial overlap in the 
regional ADCs between glioma of different grades (19,89). Therefore, further studies are 
required to assess the utility of different ADC values and other diffusion metrics for grading 
astrocytic tumors at MRI. 
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AIMS OF THE STUDY 
 
The aim of this study was to evaluate the neuroradiologist`s use of advanced MRI techniques 
in the diagnosis and preoperative planning of brain tumors, with focus in the grading and 
characterization of gliomas, as well as in the assessment of the peri-enhancing region aiming 
to demonstrate tumor-infiltration and tumor-free edema. To develop and determine the 
role of the most commonly used advanced MRI techniques: DWI, MRSI, and perfusion 
imaging in the clinical decision-making process in terms of diagnostic examination 
performance. 
 
Specific aims of the individual papers 
 
 Paper I: To assess if DWI could be used to differentiate between different types of 
brain tumor and to distinguish between peri-enhancing infiltration in HGGs, 
lymphomas and pure vasogenic edema in metastases, meningiomas. 
 
 Paper II: To assess the value of MRSI in differentiating solitary brain metastases and 
HGGs in the basis of differences in metabolite ratios in the peri-enhancing region. 
 
 Paper III: To evaluate the diagnostic accuracy of DWI, MRSI, or by combining different 
parameters from these MR techniques in grading primary cerebral gliomas. 
 
 Paper IV: To compare microvascular leakage (MVL), CBV, and CBF in the distinction of 
metastasis from GBM using DSC MRI, and to estimate the diagnostic accuracy of 
perfusion and permeability MRI. 
 
 Paper V: To assess the diagnostic accuracy of MVL, CBV and CBF values derived from 
DSC MRI for grading of cerebral glial tumors, and to estimate the correlation 
between vascular permeability/perfusion parameters and tumor grades. 
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MATERIAL AND METHODS 
 
Facilities 
 
The papers of this thesis are based on MRI examinations performed in the Section of 
Neuroradiology at Oslo University Hospital, Ullevål, Oslo, Norway. All examinations were 
performed on the following scanner models: 
 1.5 T MR imaging unit: Magnetom Sonata, Siemens; papers I, II and III.
 3 T whole-body MR imaging unit system: Sigma HDx, GE Medical systems; papers 
IV and V. 
 
Patients and histopathologic diagnosis 
 
All patients included in the studies were diagnosed with a primary or secondary brain tumor 
between January 2006 and January 2010. The patients and tumor materials for the different 
studies are summarized in Table 2. 
 
Histopathologic diagnosis was based according to the World Health Organization (WHO) 
classification (143). 
 
Table 2. Summary of materials in the different studies. 
Study 
 
I II III IV V 
Years of 
diagnosis 
2006-2007 2006-2007 2006-2007 2007-2009 2007-2010 
Number of 
patients 
93 73 74 61 79 
Histologic 
diagnosis* 
59 HGGs: 
37 GBM, 22 AA; 
23 MET; 
5 lymphomas; 
6 MEN 
53 HGGs: 
34 GBM,19 AA; 
20 MET 
59 HGGs: 
 37 GBM,22 AA; 
15 LGGs 
40 HGGs:  
40 GBM; 
21 MET 
18 LGGs:  
18 grade II; 
61 HGGs:  
14 grade III,
47 grade IV 
Advanced MRI 
technique 
DWI MRSI DWI+MRSI PWI PWI 
HGGs: high-grade gliomas; LGGs: low-grade gliomas; GBM: glioblastoma multiforme; AA: anaplastic astrocytoma; MET: 
metastases; MEN: meningioma; *: WHO classification; DWI: diffusion-weighted imaging; MRSI: magnetic resonance 
spectroscopic imaging; PWI: perfusion and permeability imaging.  
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Pulse sequences 
 
Summaries of MRI parameters are shown in Tables 3 and 4, respectively. 
In study I and III, DWI was acquired in the transverse plane by using a single-shot SE echo-
planar sequence with diffusion gradient encoding in three orthogonal directions. The 
parameters for DWI were as follows: TR/TE 3100/96 ms, matrix size 128 x 128, FOV 211 mm, 
slice thickness 5 mm, intersection gap 1.5 mm, and b values of 0, 500, and 1000 sec/mm2. 
ADC maps were calculated on a pixel-by-pixel basis with software incorporated in the MRI 
unit (workstation). 
 
In study II and III, multivoxel 2D CSI with VOI positioning on three reference images was 
performed using the following parameters: SE sequence with automatic dynamic high-order 
shimming and Gaussian water suppression, TR 1500 ms, TE 30 and 135 ms, FOV 160 mm, 
slice thickness 15 and 10 mm, and 4 acquisition averages. A VOI of 80 x 80 mm was placed 
innside a FOV of 160 x 160 mm on a 10- or -15 mm transverse section in most examinations. 
Voxel sizes for 2D CSI studies were thus tipically 1x1x1 cm or 1x1x1.5 cm. 
 
In study IV and V, DSC MRI was performed using a T2*-weighted single-shot gradient-echo 
echo-planar imaging during contrast medium administration. Parameters of the sequence 
were TR/TE of 1500/30 ms, FOV of 240 x 240 mm, matrix size of 96 x 128, slice thickness of 5 
mm, interslice gap of 0, flip angle of 60, array spatial-sensitivity encoding technique with 
aceleration factor=2, number of slices of 26, acquisition time of 80 s, and 53 images were 
obtained at intervals equal to the repetition time. After 7 s, a 18-ml contrast bolus of 
gadopentate dimeglumine (0.5 mmol/ml) was administered intravenously using an MR-
compatible power injector at a rate of 5 ml/s, and immediately followed by a 15-ml bolus of 
saline injected at a rate of 5 ml/s through an antecubital angiocatheter. 
 
Table 3. Conventional MRI parameters on a 1.5T MR imaging unit used in paper I, II and III. 
 
Technique T1-w SE T2-w SE FLAIR MPRAGE T1-w postcontrast 
 
TR (ms) 500  4650  8500  1900  
TE (ms) 7.7  79  117  4.38  
TI (ms) - - 2500  - 
FOV(mm) 270  230  230  230  
Matrix size 144x256 192x256 147x256 256x256 
Slice thickness (mm) 5  5  4 1  
Slice gap (mm) 1  1  0.6  - 
averages 2 2 2 1 
TR: repetition time; TE: echo time; TI: inversion time; FOV: field of view; SE: spin echo; FLAIR: fluid-attenuated inversion-
recovery; MPRAGE: magnetization prepared rapid acquisition gradient echo T1-weighted. 
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Table 4. Conventional MRI parameters on a 3 T MR imaging unit used in paper IV and V. 
 
Technique T1 IR T2 FLAIR T1-w SE postcontrast 
 
3D-SPGR 
postcontrast 
TR (ms) 2500 6000 9500 675 7.8 
TE (ms) 9.6 95 120 13 3 
TI (ms) 920 - 2250 - - 
FOV(mm) 240x240 240x240 240x240 240x240 256x256 
Matrix size 384x224 480x480 384x224 384x224 256x256 
Slice thickness (mm) 5 5 5 5 1 
Slice gap (mm) 1.5 1 1.5 - - 
TR: repetition time; TE: echo time; TI: inversion time; FOV: field of view; SE: spin echo; FLAIR: fluid-attenuated inversion-
recovery 3D-SPGR: three- dimensional isotropic spoiled gradient echo.
 
Data evaluation/Imaging analysis 
 
DWI data evaluation (study I and III) 
 
ADC maps were calculated on a pixel-by-pixel basis with software incorporated in the MR 
imaging unit (workstation) operating with the ROIs. Round-shaped ROIs were placed over 
three areas within the tumors (ADCt) corresponding to the enhancing region or the solid 
portion of tumor, in three areas with peritumoral edema (ADCe), in three areas in 
contralateral normal-appearing white matter (ADCn).  ADC ratios were calculated by dividing 
the value in either the tumor or in the peritumoral edema by the value in the contralateral 
normal-appearing white matter (ADCt ratio and ADCe ratio, respectively), and by dividing the 
value in the tumor by the value in the peritumoral edema (ADCt/e ratio). Then the minimum, 
the maximum, and the mean of ADCt, ADCe, ADCn, ADCt ratio, ADCe ratio, and ADCt/e ratio 
were selected for analysis. The ADC values represent averaged ADCs of three ROIs. 
 
MRSI data evaluation (study II and III) 
 
The spectra were automatically analyzed for the relative signal intensities (areas under the 
fitted peaks in the time domain) of the following metabolites: Cho, Cr, and NAA. The 
following ratios were calculated: Cho/Cr, Cho/NAA, and NAA/Cr (this ratio only in study II) at 
TE 135 ms. Postprocessing steps, including frequency shift, baseline correction, phase 
correction, and peak fitting/analysis, were performed first automatically and then manually 
if necessary using the software package provided by the manufacturer (Syngo MR 2004 A/V; 
Siemens, Erlangen, Germany). All spectra analyses were performed in a window from 0.50 to 
4.30 ppm (using the standard method of assigning a shift value of 4.7 ppm to the measured 
unsuppressed water peak). The maximum values of Cho/Cr and Cho/NAA ratios were 
obtained from spectral maps in the three aforementioned locations: enhancing tumor, 
peritumoral edema, and normal-appearing white matter avoiding as far as possible cystic or 
necrotic regions and adjacent normal tissues in an attempt to mimimize the contribution of 
partial volume effect. In addition in study II, all spectra were inspected for the presence of 
Lip (and/or Lac) at TE 30 ms. We considered that peaks at 1.3 and 0.9 ppm at short TE (30 
ms) primarily consisted of Lip, and in some cases, secondarily, the peak at 1.3 ppm may also 
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contain a contribution from Lac, but this is obscured by the Lip peak. Therefore, we have 
used the term combined Lip/Lac (LL). 
 
Imaging analysis of rCBV, rCBF, and MVL measurements using DSC MRI 
(study IV and V) 
 
The rCBV and the rCBF were generated using established tracer kinetic models applied to the 
first-pass data (91,144). The dynamic curves were mathematically corrected to reduce 
contrast-agent leakage effects in the tumor due to BBB disruption (100).  
 
In areas with contrast-agent leakage, the relaxivity-time curve can go down below zero due 
to the T1 shorting effect of contrast agent. Linear fitting is used to estimate the T1 effect, 
and by removing the leakage term, both a corrected CBV map and a first-order estimate of 
the vascular permeability is generated (100). This is a MVL (K2) map where the pixel intensity 
is proportional to the rate of contrast agent leakage from intra- to extravascular space. 
 
 The measurements of CBV and CBF were obtained from perfusion maps with automatic 
vessel segmentation; this segmentation was corrected using mean transit time masks, in 
order to avoid the risks of calculating maps from vessels (116). The ROIs positioned on the 
CBV vessel segmentation maps were then automatically transferred onto the corresponding 
postcontrast T1-weighted image dataset in order to ensure that we have placed the ROIs 
correctly in the solid portion of the tumor and that large vessels within the ROIs had been 
avoided to minimize volume averaging. 
 
CBV and CBF values were performed using ROIs. Multiple measurements were manually 
drawn in areas with maximum signal enhancement on color-coded DSC CBV and CBF maps, 
and the highest CBV and CBF values were obtained from these ROIs. This method for the 
measurement of maximal abnormality provides the highest intraobserver and interobserver 
reproducibility in CBV measurements (145). To minimize confounding factors in CBV and CBF 
analysis, the size of the ROIs were kept constant (12x12 pixels, 17.58 mm2). The ROIs were 
selected from within the tumor, the peri-enhancing region, and the contralateral normal-
appearing white matter avoiding as far as possible areas of necrotic tissue, cysts, or large 
vessels as noted above. The rCBV and rCBF ratios were calculated by dividing the maximum 
value in either the tumor or in the peri-enhancing region by the value in the contralateral 
normal-appearing white matter (rCBVt, rCBFt, rCBVe, and rCBFe) and by dividing the value in 
the tumor by the value in the peri-enhancing region (rCBVt/e and rCBFt/e). Then the 
maximum of rCBVt, rCBFt, rCBVe, rCBFe, rCBVt/e, and rvCBFt/e were selected for analysis. 
 
MVL measurements were obtained by simultaneously viewing postcontrast-T1-weighted 
images and corresponding perfusion permeability maps on the workstation, using the 
software NordicICE. The MVL map was automatically transferred onto the corresponding 
axial contrast-enhanced T1-weighted image. ROIs were selected in the tumoral regions 
having the highest MVL values. Maximum and mean MVL were obtained from the ROIs. 
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Analysis software 
 
In the studies I, II and III the metabolite ratios, ADC values and ratios were calculated using 
the software package provided by the manufacturer (Syngo MR 2004 A/V; Siemens, 
Erlangen, Germany). 
 
Imaging analysis of rCBV, rCBF, and MVL values derived from DSC MRI were postprocessed 
with a dedicated software package (NordicICE- Nordic Image Control and Evaluation version 
2.3.4; Nordic Imaging Lab, Bergen, Norway, http://www.nordicneurolab.no), in the study IV 
and V. 
 
Statistical analysis were performed using the software package R: a language and 
environment for statistical computings. R Foundation for statistical computings, Vienna, 
Austria (146), in the study I, II and III. In the study IV and V, the statistical analysis was 
performed using Sigmal Plot software (SPSS Science 15.0 Chicago. Il, USA). 
 
Statistical analysis 
 
In all papers a p-value of <0.05 was considered to be statistically significant. 
 
Papers I, II and III 
 
ANOVA was used to calculate whether the four tumor groups showed significant differences 
according to the different ADC values and ratios or not (study I). Pairwise diferences of the 
significant ADC values was performed with Turkey´s T-procedure for multiple comparisons 
together with Westfall adjustment method (study I). The comparisons of the metabolite 
ratios within the tumor and the peritumoral edema of HGGs and metastases were calculated 
by the t test for log-normal distribuited data (study II). Statistical comparisons of ADC and 
MRSI values in tumor and peritumoral edema for LGGs and HGGs have been done by the t 
test for independent groups (study III). 
 
Spearman and Pearson correlation factor were determined between minimum ADCt values, 
ratio of tumoral Cho/NAA, and tumor grade (study III).  
 
Receiver operating characteristics (ROC) curves analysis based on logistic regression models 
were performed in order to identify the optimal cutoff values for predicting purposes of 
HGGs versus metastases (study I and II), and HGGs versus LGGs (study III). In study I, a 
multifactorial logistic regression was done step-wise by taking the area under the curve 
(AUC), Akaines information criteria (AIC) and significance of the interesting factors as 
criteria. In study III, a 10-fold cross-validation was performed for logistic regression models 
including at least two variables as predictors. 
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Papers IV and V 
 
The data are presented as the mean value  SD, median and range. Statistical comparisons 
of data sets were performed with the use of Student´s t test when the data sets complied 
with the conditions of normality and equal variance. Under other conditions we performed 
the comparisons by nonparametric analysis using the Mann-Whitney rank sum test. 
 
Correlation analysis between parameters were searched for by linear regression analysis, 
using the correlation coefficient Pearson (study IV and V) and Spearman (study IV). 
 
Cutoff values of different permeability and perfusion parameters rCBVe, rCBVt/e, rCBFe, 
rCBFt/e, and maximum MVL for distinguishing metastases from GBM (study IV) and cutoff 
values of rCBVt, rCBVe, rCBFt, rCBFt/e, median and maximum MVL for distinguishing across 
histologically defined tumor grades (paper V) were determined by ROC curve analysis. The 
ROC curve was further used to calculate the AUC, which is an index of the overall diagnostic 
performance of a test. Sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) as well as accuracy were reported for the optimal thresholds. In the 
paper V, a forward stepwise regression analysis (SLR) using the parameters rCBVt, rCBFt, and 
maximum MVL was performed. 
 
Ethics 
 
Informed consent was obtained from all subjects before the study using a protocol approved 
by the Regional Comittee for Medical Research Ethics in Norway, and according to the 
guidelines of this Comittee. 
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RESULTS AND SUMMARY OF THE PAPERS 
 
Paper I.  
 
Quantitative apparent diffusion coefficients in the characterization of brain 
tumors and associated peritumoral edema. 
Acta Radiol 2009 Jul;50(6):682-689. 
 
Background: Conventional MRI has a number of limitations in the diagnosis of the most 
commom intracranial brain tumors, including tumor specification and the detection of 
tumoral infiltration in regions of peritumoral edema. 
 
Results: Statistically significant differences were found for minimum and mean of ADCt and 
ADCt ratio values between metastases and HGGs when including only one factor at a time 
(Figure 8).  
 
ROC analysis for each ADC value as a single factor, found the minimum ADCt ratio to be the 
best predicitive indicator, with an AUC of 0.73. Including a combination of in total four 
parameters (mean ADCt, and minimum, maximum and mean ADCt ratio) resulted in 
sensitivity, specificity, PPV, and NPV of 72.9%, 82.6%, 91.5%, and 54.3% respectively. In the 
ROC curve analysis, the AUC of the combined four parameters was the largest (0.84), 
indicating a good test (Figure 9). 
 
Conclusion: Our results suggest that ADC values and ratios (minimum and mean of ADCt and 
ADCt ratio) may be helpful in the differentiation of metastases from HGGs. ADC values and 
ADC ratios in peritumoral edema cannot be used to differentiate edema with infiltration of 
tumor cells from vasogenic edema. 
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Figure 8. Box plots show comparison of apparent 
diffusion coefficient (ADC) measurements (minimum 
ADC tumor values) according to four groups of 
cerebral tumors. Minumum ADC values differed 
significantly between high-grade gliomas and 
metastases (p<0.028). No significance difference is 
present among the others cerebral tumors.   
Figure 9. ROC curve for mean ADC tumor, minimum ADC tumor 
ratio, maximum ADC tumor ratio, and mean ADC tumor ratio for 
differentiation between high-grade gliomas and metastases. 
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Paper II.  
 
Proton magnetic resonance spectroscopy in the distinction of high-grade 
cerebral gliomas from single metastatic brain tumors. 
Acta Radiol 2010 Apr;51(3):316-325. 
 
Background: Brain metastases and primary HGGs, including GBMs and anaplastic 
astrocytomas (AA), may be indistinguishable by conventional MRI. Identification of these 
tumors may have therapeutic consequences. 
 
Results: Significant differences were noted in the peritumoral Cho/Cr, Cho/NAA, and NAA/Cr 
ratios between HGGs/GBMs/AA and metastases. 
 
Example of GBM is given in Figure 10. 
  
ROC analysis demonstrated a cutoff value of 1.24 for peritumoral Cho/Cr ratio to provide 
sensitivity, specificity, PPV, and NPV of 100%, 88.9%, 80.0%, and 100% respectively, for 
discrimination between HGGs and metastases. By using a cutoff value of 1.11 for 
peritumoral Cho/NAA ratio, the sensitivity was 100%, the specificity was 91.1%, the PPV was 
83.3%, and the NPV was 100% (Figure 11). 
 
Conclusion: The results of this study demonstrate that MRS can differentiate HGGs from 
metastases, especially with peritumoral measurements, supporting the hypothesis that MRS 
can detect infiltration of tumor cells in the peritumoral edema. 
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Figure 10. 60-year-old woman with a glioblastoma multiforme. a Axial post-contrast T1-weighted image reveals an 
enhancing mass with heterogeneous signal intensity and central necrosis in the right posterior temporal region. b Spectrum 
(TE 135ms) from within the anterior peri-enhancing region demonstrating increase in Cho/Cr and in Cho/NAA from tumoral 
infiltration of adjacent peri-enhancing tissues. Note the presence of inverted lactate doublet at 1.3 ppm. c Spectrum (TE 
135ms) from within the tumor shows an increase in the Cho peak, a reduction in NAA and Cr consistent with neoplasm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure11. Graph shows five receiver operating 
characteristic (ROC) curves of intratumoral Cho/Cr and 
NAA/Cr ratios (chocrt, NAAcrt) and peritumoral Cho/Cr, 
Cho/NAA, and NAA/Cr ratios (chocre, choNAAe, and 
NAAcre) for differentiation of high-grade gliomas from 
metastases. 
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Paper III.  
 
Measurements of diagnostic examination performance using quantitative 
apparent diffusion coefficient and proton MR spectroscopic imaging in the 
preoperative evaluation of tumor grade in cerebral gliomas. 
 Eur J Radiol 2010, doi: 10.1016/j.ejrad.2010.07.017 
 
Background: Tumor grading is very important both in treatment decision and evaluation of 
prognosis. While tissue samples are obtained as part of most therapeutic approaches, 
factors that may result in inaccurate grading due to sampling error, have led to a desire to 
use imaging better to ascertain tumor grade. 
 
Results: The minimum, maximum and mean ADCt values and ADCt ratios were statistically 
significant in the difference between LGGs from HGGs. The metabolite ratios of Cho/Cr and 
Cho/NAA in the peritumoral edema were statistically significant different between LGGs and 
HGGs. 
 
Statistical analysis demonstrated a threshold minimum ADCt value of 1.07 to provide 
sensitivity, specificity, PPV, and NPV of 79.7%, 60.0%, 88.7%, and 42.9% respectively, in 
determining HGGs. Threshold values of 1.35 and 1.78 for peritumoral Cho/Cr and Cho/NAA 
metabolite ratios resulted in sensitivity, specificity, PPV, and NPV OF 83.3%, 85.1%, 41.7%, 
97.6%, and 100%, 57.4%, 23.1% and 100% respectively for determining HGGs.  
 
Step-up ROC analysis on the potential multifactorial models lead to an optimal logistic 
regression model including the following four factors with two-way interaction: mean ADCt 
value, maximum ADCt ratio, peritumoral Cho/Cr and Cho/NAA metabolite ratios. A threshold 
value of 0.900 (logistic regression fitted value) for the combined four parameters provided a 
sensitivity of 91.5%, a specificity of 100%, a PPV of 100%, a NPV of 60%, AUC of 98.2 %, and 
accuracy of 92,5%. 
 
Examples of low-grade astrocytoma and GBM using DWI, and GBM using MRSI are given in 
Figures 12, 13, and 14. 
 
Conclusion: Combining DWI and MRSI increases the accuracy of preoperative imaging in the 
determination of glioma grade. MRSI had superior diagnostic performance in predicting 
glioma grade compared with DWI alone. The predictive values are helpful in the clinical 
decision-making process to evaluate the histologic grade of tumors, and provide a means of 
guiding treatment. 
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Figure 14. Glioblastoma multiforme. a Axial T1-weighted image after contrast administration demonstrates an infiltrating 
necrotic mass with scattered irregular enhancement in the right temporal area. b Spectrum (TE 135 ms) from within the 
lesion demonstrating increase in Cho/Cr and in Cho/NAA. c Spectrum (TE 135 ms) from within anterior peri-tumoral region 
shows marked cho elevation with respect to Cr and NAA  indicating tumor infiltration. 
Figure 12. Low-grade astrocytoma (WHO grade II) in a 32-
year-old woman. a Post-contrast T1-weighted image shows 
a slightly hypointense lesion and no enhancement in the 
left temporal lobe. b ADC map (minimum ADC tumor value) 
shows hyperintensity in the lesion (1.30x10-3mm2 /sec). 
Figure 13. Glioblastoma multiforme (WHO grade IV) in a 
60-year-old woman. a Post-contrast T1-weighted image 
shows an enhancing mass in the left parietal area. b ADC 
map (minimum ADC tumor value) shows strongly 
hypointensity in the lesion (0.566x10-3 mm2/sec). This 
finding may correspond to the cellularity of the tumor. 
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Paper IV.  
 
Diagnostic examination performance by using microvascular leakage, cerebral 
blood volume, and blood flow derived from 3-T dynamic susceptibility-
weighted contrast-enhanced perfusion MR imaging in the differentiation of 
glioblastoma multiforme and brain metastasis.  
Neuroradiology 2010, DOI: 10.1007/s00234-010-0740-3 
 
Background: Conventional MRI has a limited capacity to differentiate between GBM and 
single brain metastasis, because of their similar imaging appearance. It is clinically important 
to distinguish GBM from a single brain metastasis, because medical staging, surgical 
planning, and therapeutic decisions are vastly different for each tumor type and can 
potentially affect the clinical outcome. 
 
Results: The differences of rCBVe, rCBVt/e, rCBFe, and rCBFt/e between GBM and 
metastases were statistically significant (p<0.0001). Metastases had significantly lower MVL 
maximum values than GBM (p=0.005). The values are summarized in Figures 15 and 16. 
 
The optimal cutoff value for differentiating GBM from metastasis was 0.80 which implies a 
sensitivity of 95%, a specificity of 92%, a PPV of 86%, a NPV of 97%, accuracy 93%, and AUC 
of 0.98 for rCBVe ratio. 
 
There was modest correlation between measured values of rCBVt and rCBFt, with 
Spearman`s r=0.35 (p=0.005) and Pearson`s r=0.36 (p=0.004) for all brain tumors. 
 
Representative cases of metastasis and GBM are shown in Figures 17 and 18. 
 
Conclusion:  MVL measurements in GBMs are significantly higher than those in metastases. 
Statistically, both rCBVe, rCBVt/e and rCBFe, rCBFt/e were useful in differentiating between 
GBMs and metastases, supporting the hypothesis that perfusion MRI can detect infiltration 
of tumor cells in the peri-enhancing region. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 15. Scatterplot of the maximum rCBVt, rCBVe, and rCBVt/e measurements for all 
individual cases in brain metastases (MET) and 
glioblastomas (GBM). 
Figure 16. Scatterplot of the maximum rCBFt, 
rCBFe, and rCBFt/e measurements for all individual 
cases in brain metastases (MET) and glioblastomas 
(GBM). 
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Figure 17.  A 52-year-old woman with a histologically verified 
metastasis from lung carcinoma in the right frontal lobe. a 
Post-contrast T1-weighted image demonstrates intense and 
inhomogeneous enhancement with central necrosis. b and c 
Axial DSC MRI perfusion images with rCBV (b) and rCBF (c) 
maps, demonstrating increase in tumor perfusion confined to 
the enhancing tumor but not within the peritumoral region, 
indicating a non-infiltrative lesion like a metastasis. d Axial 
microvascular leakage color map overlayed onto postcontrast 
T1-weighted image shows intermediate permeability in the 
solid portion of the tumor. 
Figure 18. A 60-year-old woman with a histologically verified 
glioblastoma multiforme in the right frontal lobe. a Post-
contrast axial T1-weighted image shows a thick and irregular 
ring-like enhancing mass with central necrosis. b and c  Axial 
DSC MRI perfusion images with rCBV(b) and rCBF (c) maps, 
showing  a lesion with very high perfusion within the tumor. 
Note that there is increased perfusion around the periphery 
of the lesion (region of interest), indicating tumoral 
infiltration in the surrounding edema. d Axial microvascular 
leakage color map overlayed onto postcontrast T1-weighted 
image shows markedly elevated permeability. 
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Paper V.  
 
Measurements of diagnostic examination performance and correlation 
analysis using microvascular leakage, cerebral blood volume, and blood flow 
derived from 3-T dynamic susceptibility-weighted contrast-enhanced 
perfusion MR imaging in glial tumor grading. 
Neuroradiology 2010, DOI: 10.1007/s00234-010-0770-x 
 
Background: Grading of gliomas is important for the determination of appropriate treatment 
strategies and in the assessment of prognosis because HGGs are usually treated with tumor 
resection and additional radiotherapy and chemotherapy, whereas in LGGs, only surgical 
treatment for histological confirmation or tumor resection is performed in most patients. 
 
Results: The differences in rCBVt and the maximum MVL values were statistically significant 
among all tumor grades. 
 
Correlation analysis using Pearson was as follows: rCBVt and tumor grade, r=0.774; rCBFt 
and tumor grade, r=0.417; MVLmax and tumor grade, r=0.559; MVLmax and rCBVt, r=0.440; 
MVLmax and rCBFt, r=0.192; and rCBVt and rCBFt, r=0.605. Table 5 summarizes the 
correlation analysis. 
 
In the ROC curve analysis, the AUC of the quantitative parameter rCBVt was the largest for 
distinguishing grade II from grades III-IV (97.4%) as you can see in Figure 19, grade II from 
grade III (89.7%), and grade II from grade IV (99.7%). The ROC analysis indicated that the 
diagnostic model based on rCBVt alone had significantly higher AUC (99.7%, 97.4%) than did 
the model based on MVLmax alone (88.5%, 85.9%) in terms of AUC (p=0.034, p=0.049) 
respectively) in differentiating between grade II and grade IV or III-IV, but not between other 
tumor grades. The ROC analysis indicated that the diagnostic model based on rCBVt with 
MVLmax had no significantly higher AUC than the model based on rCBVt or MVLmax alone in 
terms of AUC in differentitating between grades III and IV. 
 
Example of WHO grade IV GBM with the respective MVLmax color overlay map is shown in 
Figure 20.  
 
Conclusion:    Both rCBVt and MVLmax showed good discriminative power in distinguishing all 
tumor grades. rCBVt correlated strongly with tumor grade; the correlation between MVLmax 
and tumor grade was moderate. 
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Table 5. Correlation values (Pearson) and significance of the correlation between each of the 
variables and grades. 
 
  Corr. Coefficient (r) P-value  N 
WHO grade vs. rCBVt 
 
 
 
0.744 
 
<0.0001 
 
79 
    
WHO grade vs. rCBFt 
 
 
 
0.417 
 
0.00013  
 
79 
    
WHO grade vs. MVL max 
 
 
 
0.559 
 
<0.0001 
 
79 
    
MVL max vs. rCBVt 
 
 
 
0.440 
 
<0.0001 
 
79 
    
MVL max vs. rCBFt 
 
 
 
0.192 
 
0.0905 
 
79 
    
rCBVt vs. CBFt 
 
 
 
0.605 
 
<0.0001 
 
79 
    
WHO World Health organization, rCBVt or rCBFt cerebral blood volume or flow in the tumor /normal tissue 
ratio, MVL microvascular leakage, max maximum 
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Figure 20. A 63-year-old-man with a histologically verified glioblastoma multiforme. a Axial 
postcontrast T1-weighted image demonstrates a mass with intense enhancement in the right 
temporal region. b Microvascular leakage color map shows elevated permeability. c Axial 
microvascular leakage color map overlayed onto postcontrast T1-weighted image shows increased 
permeability. 
Figure 19. Graph shows four receiver 
operating characteristic (ROC) curves of rCBVt, 
rCBVe, rCBFt, and MVLmax for differentiation of 
grade II from grade III-IV.  
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DISCUSSION 
 
Diffusion imaging of brain tumors (Paper I) 
 
The gold standard for brain tumor diagnosis is light microscopy analysis of histologic tissue 
samples. Typically, definitive diagnosis and differentiation between pathologic and normal 
tissue are achieved by an examination of cell architecture parameters, such as cell 
arrangement, cell density, cell size distribution and nucleus to cytoplasma size ratio. MR 
diffusion imaging probes water molecular diffusion over distances that correspond to typical 
cell sizes, and this water diffusion is also impeded by membranes, i.e. structures that are an 
integral part of the cell architecture. With increasing cell density, the impeding effect of 
membranes is expected to increase. Thus, MR diffusion imaging provides an intriguing access 
to information that otherwise can only be obtained by invasive light microscopy (128). 
 
Evaluating the peritumoral abnormality 
 
In this paper, one of the purposes was to assess the utility of ADC for distinguishing 
combined microscopic tumor infiltration and vasogenic edema around high-grade gliomas 
from pure vasogenic edema and increased interstitial fluid in cases of meningioma and 
metastatic brain tumor. Discriminating “tumor –infiltrated edema” from “vasogenic edema” 
is benefitial for achieving accurate presurgical diagnosis (147). 
 
In our study, the ADC values and ADC ratios for peritumoral edema did not differ 
significantly among patients with HGGs and metastases; therefore, DWI was not useful in 
determining the presence of peritumoral neoplastic cell infiltration. This is in agreement with 
van Westen et al. (141), and recently Wang et al. (148) reported that the ADC values of the 
peritumoral region of metastatic brain tumors did not differ compared to those of GBM. 
Earlier DTI studies by Lu et al. (139), reported a significant difference between tumor-
infiltrated edema and pure vasogenic edema using a parameter called “tumor infiltrative 
index” and also reported increased ADC in metastasis compared to GBMs. However, another 
study demonstrated reduced ADC in the peritumoral region of metastases compared to that 
of GBMs (149). The discrepancy between these studies may be due to the difference in the 
selection of ROIs for the peritumoral region (148). In a recent paper by Wang et al. (148), 
using a semi-automated segmentation technique to separate different regions of the tumor 
and peritumoral edema, was obtained a significant difference in FA, CL and CP between 
GBMs and metastases, but not with ADC as mentioned above. 
 
Furthermore, in our study the ADC values and the ADC ratios for peritumoral edema did not 
differ significantly between HGGs and meningiomas. This is in conflict with some previous 
studies and in agreement with others. Some studies have demonstrated a significant 
difference in peritumoral ADC and FA between low-grade meningiomas and HGGs (150), 
possibly reflecting the presence of tumor-infiltrated edema in gliomas. Likewise, Lu et al. 
(151) found a difference in peritumoral ADC when comparing 12 HGGs and 12 meningiomas 
in a first study. However, in a second study that included 10 HGGs, 10 LGGs, 10 
meningiomas, and 10 metastases, the same authors failed to reproduce these findings (139). 
On the other hand, Provenzale et al. (152) found no significant difference in the increased 
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ADC values in either peritumoral hyperintense regions or peritumoral normal-appearing 
white matter between meningiomas and HGGs. 
 
This lack of converging evidence may suggest that the usefulness of ADC for characterization 
of peritumoral signal changes is doubtful (141). 
 
MR diffusion: Tissue characterization 
 
The rate of microscopic water diffusion within tissues can be evaluated with DWI. ADC 
values have been assessed for differentiation between tumor types; however, there can be 
also overlap between (153,154,155). GBMs, metastatic tumors and primary central nervous 
system lymphomas (PCNSL) are sometimes difficult to differentiate from each other when 
only conventional MRI studies are available because they ususally manifest as enhanced 
masses (155). 
 
The presence of a solitary brain tumor in an adult can pose a clinical dilemma, especially 
when a systemic cancer is not known or not found after complete medical workup (117). Our 
study showed that the minimum and mean ADCt values and ADCt ratios of metastases were 
significantly lower than those in HGGs. This is in conflict with some previous studies and in 
agreement with others. Krabbe et al. (130) found that the ADC of GBMs was lower than that 
of metastatic tumors. Likewise, Chiang et al (75) found that the mean ADC values at 
contrast-enhancing areas of metastases to be significantly higher than those in HGGs. 
Nevertheless, in the study of Krabbe et al. (130) diffusion was measured in a single axial slice 
sensitive to diffusion only along the cephalocaudal axis, and all of these studies have the 
limitation of including relatively small sample population. Several authors (136,148,155) 
found that the ADC values were not significantly different between the two groups. On the 
other hand, Bulakbasi et al. (132) found that the normalized ADC ratios from metastatic 
tumor areas (equivalent to our mean ADCt ratios) were significantly lower than those of 
high-grade astrocytomas, in accordance with our results. 
 
Differentiation of PCNSL from HGG is of utmost importance for correct treatment. For 
example, primary therapy for high-grade astrocytic tumor almost always includes surgical 
resection whereas lymphoma is managed primarily with chemotherapy or radiation therapy 
after stereotactic biopsy (156). In our study, the ADC values (ADCt) and the ADC ratios (ADCt 
ratio, ADCt/e ratio) of PCNSL were lower than those of HGGs; however, the difference 
between the two populations was not statistically significant, in disagreement with the 
result of other studies (127,135,136,155). Our results showed a mean ADCt value of 0.732 ± 
0.17 x 10-3mm2/s. Recently, Toh et al. (127) have reported a value of 0.630 ± 0.155, and 
Horger et al. (156) have reported a mean ADC of 0.71 ± 0.13 x 10-3mm2/s. Differences in 
group size may contribute to results varying across studies. In our study, we included only 
five patients with PCNSL compared to a relatively large group of HGGs (59 patients). The 
study of Toh et al. (127) included only ten patients, Guo et al. (135) 11 patients, Calli et al. 
(136) and Yamasaki et al. (155) both eight patients, and recently in a study by Horger et al. 
(156) were included nine patients with PCNSL. 
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Finally, our results showed that the ADC values were not useful for differentiation between 
lymphomas and metastases; contrary to a study by Yamasaki et al. (155) who found that the 
ADC of malignant lymphomas was lower than that of metastatic tumors. 
 
Stepwise logistic regression (SLR) performance 
 
Our intention was to determine whether the combination of four parameters: mean ADCt 
value, minimum, maximum and mean ADCt ratio using step-up ROC analysis could increase 
the accuracy in differentiation between HGG and metastasis. The current results of this 
study demonstrate that the SLR model provides higher diagnostic accuracy compared to the 
best performing single parameter (the minimum ADCt ratio) in differentiating HGG from 
metastasis. 
 
MRSI: Metastatic neoplasm versus high-grade glioma (Paper II). 
 
Solitary brain metastases may be indistinguishable from a primary glioma by conventional 
MRI (23). The ability of MRS to differentiate gliomas from metastases remains controversial 
(22,87,88). Burtscher et al. (157) showed that HGGs could be differentiated from metastases 
by the presence of abnormal spectra in the normal-appearing brain tissue adjacent to the 
lesion. Ishimaru et al. (74) showed that the absence of intratumoral Cr peak was suggestive 
of metastases, since 21 of 25 metastases in this study had no definitive Cr peak. In addition, 
the authors noticed that the absence of Lip signal at a TE of 30 ms could exclude the 
diagnosis of metastasis. However, in areas of central necrosis in HGGs, there is also often Lip 
and Lac, as well as a lack of Cr, so the intratumoral spectrum is often non-specific (23). Many 
other spectral patterns have been reported (22), but further studies are required. 
 
MRSI in the peritumoral tumor region 
 
In the present study, the metabolite ratios of Cho/Cr, Cho/NAA, and NAA/Cr at intermediate 
TE obtained from the peritumoral edema of HGGs, GBM, and AA versus metastases were 
statistically significant. This difference in the tumor-associated vasogenic edema can be in 
part be explained by the difference in pathophysiology (158,159,160,161,162). 
 
Brain tumor edema occurs when plasma-like fluid enters the brain extracellular space 
through impaired capillary endothelial tight junctions in tumors. Recent evidence suggests 
that the membrane water channel protein aquaporin-4 (AQP4) plays a role in brain tumor 
edema (163). In HGGs, the peritumoral edematous region represents a combination of 
vasogenic edema and neoplastic cell infiltration (158,164,165,166,167). Recently, Engelhorn 
et al. (168) identified that the so-called perifocal edema not only includes invading tumor 
cells but also is associated with glial alterations in vital brain tissue, i.e astrocytic swelling, 
microglial accumulation, and microglial activation. On the other hand, in the case of brain 
metastases, the peritumoral edema is purely vasogenic. There is increased extracellular 
water due to leakage of plasma fluid from altered tumor capillaries, but not tumor cells are 
present (158,164,169). 
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Our finding that the Cho/Cr ratio in peritumoral edema of HGGs was higher than those of 
metastases is consistent with previous observations (75,106). Weber et al. (109) reported 
elevated Cho/NAA ratios in the perifocal T2-weighted hyperintense region in cases of 
gliomas but no in metastases, in accordance with our results. These results support the 
previous findings that peritumoral edema associated with HGGs is characterized by 
extensive infiltration of tumor cells (170), whereas peritumoral region in metastases 
contained no tumor cells or vascular endothelial proliferation but almost purely vasogenic 
edema (106,109,157,171). 
 
In our study, peritumoral Cho/Cr and Cho/NAA ratios have similar sensitivities (100%) in 
differentiating HGGs from metastases. Furthermore, the AUC values using peritumoral 
Cho/Cr and Cho/NAA ratios for discrimination of GBM from metastases were 93.9% and 
97.9%, respectively. This is in accordance with Weber et al (109), who found AUC values of 
96% and 95% respectively. Thus, MRS is able to differentiate HGGs from metastases through 
analysis of the peritumoral edema. 
 
Intratumoral MRSI 
 
In our study, the intratumoral Cho/Cr ratio in HGGs and GBM differed statistically from those 
seen in metastases, in disagreement with previous reported data (75,109). However, our 
data are in accordance with Law et al (106), who reported a substantial difference in the 
intratumoral Cho/Cr ratio between gliomas and metastases.  
 
Although we found a difference in the intratumoral Cho/Cr ratio between HGG/GBM and 
metastases, the ROC curves showed low sensitivity (45%), indicating that the true-positive 
rates are relatively low and false-negative rates are correspondingly high, indicating that this 
parameter is not clinically useful in the distinction between HGGs from metastases, and that 
caution in the clinical setting should be considered. 
 
Diagnostic value of combined use of diffusion imaging and MR 
spectroscopy in glioma grading (Paper III). 
 
Discrimination between tumor grades is an important issue, because there is scientific 
dispute on the optimum treatment strategy for patients with low-grade tumors (172). These 
patients are sometimes subjected to clinical and radiological observation only (173,174). 
Conversely, multimodal treatment with surgical resection, radiotherapy, and chemotherapy 
is generally recommended for patients with HGG (172). Therefore, accurate discrimination 
between HGGs and LGGs is crucial to avoid over-or undertreatment. Conventional MRI 
provides only limited information on the biological behavior of a tumor, especially if 
radiographic signs of necrosis are lacking; therefore, other noninvasive methods are needed 
(172). 
 
Apparent diffusion coefficient in gliomas 
 
ADC maps obtained from DWI can provide physiologic information by detecting regional 
variation in the diffusion of free water within brain tissue (175). Prior studies have reported 
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mixed results as to the utility of ADC maps in establishing the grade of glioma, with some 
authors finding a correlation between glioma grade and ADC (8,175,176,177) and other not 
finding ADC maps useful (131,153,178). 
 
In the current study, the ADCt values and ratios were significantly different between patients 
with LGGs and HGGs. Both ADCt values and ADCt ratios were lower in HGGs (grade III and IV) 
than in LGGs (grade II). Sugahara et al. (8) showed that minimum ADC value correlated well 
with histologic cellularity and was useful for grading of gliomas. Higher ADC values in 
intracranial tumors are atribuited to low tumor cellularity, necrosis, or cysts, and lower 
values atribuited to attenuated highly cellular tumor (179). These higher ADC values in LGGs 
may reflect an increase in the water content of the interstitial spaces (180). On the other 
hand, in areas of high cellularity, there is more structure and more cell membranes when 
compared with normal brain. This situation leads to an increase in the impedance to the 
motion (diffusion) of water molecules and a decrease in the ADC (181). In addition to cell 
density of cell membrane, there are other structures, such as intracellular membranes of the 
endoplasma reticulum, that are involved in protein production. The structures may depend 
on cell activity and tissue or tumor type, and may exert considerable restriction for diffusion 
(128). However, studies by Lam et al. (178) and Rollin et al. (182) failed to find a significant 
difference between ADC values of HGGs and LGGs. 
 
Im this study, the ADC values and ratios for peritumoral edema did not differ significantly 
among patients with HGGs and LGGs in agreement with other authors (131,135,141). 
However, Guzman et al. (183) reported that HGGs have higher ADC values in the peritumoral 
edema than LGGs; nevertheless, this study has the limitation of a relatively small population. 
Early studies, however, suggest that using high b-values of up to 5000 and biexponential 
analysis of decay curves can differentiate tumor infiltration from peritumoral edema 
(181,184). 
 
The sensitivity of minimum ADCt in glioma grading  (LGGs versus HGGs) in our study was 
79.7%, indicating a moderate high true-positive rate. Hence, if the minimum ADCt is below 
1.07, there is a moderate high probability that the tumor will be a HGG. However, the 
relatively low specificity (60%) means that false-positive rates are relatively high and true-
negative rates are correspondingly low. Arvinda et al. (185) defined a threshold ADC value of 
98.50 mm2/s and obtained a sensitivity of 90% and a specificity of 87.1%. However, in this 
study, LGGs included both grades I and II gliomas, and oligodendrogliomas. In a recent paper 
Murakami et al (186) showed that minimum ADC helped distinguish grade 1-2 from grade 3-
4 tumors with 94% sensitivity and 82% specificity at a cutoff value of 1.16 x 10-3 mm2/s. 
 
There was some overlap in the ADCt values and ratios of each group, although our results 
demonstrate the potential diagnostic usefulness of the mimimum ADCt value to distinguish 
HGGs from LGGs. 
 
Diagnostic value of MRSI  in the noninvasive grading of gliomas 
 
MRSI provides estimates of the levels of cellular metabolites that may be relevant for 
evaluating the aggressiveness of tumors and for defining tumor burden 
(16,187,188,189,190). Previous studies consisted of limited number of patients with variable 
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acquisition methodology thereby restricting comparisons across different grades of tumors 
(187). Nevertheless, MRSI has become an increasingly important method in the diagnostic 
workup of patients with glioma (172). 
 
In the present study, the tumoral Cho/NAA ratio of HGGs was significantly higher than that 
of LGGs. These results were in accordance with other studies (73,179,191,192,193). No 
significant differences were noted in the tumoral Cho/Cr ratio between LGGs and HGGs, in 
disagreement with the results of other authors (9,73,172,193); nevertheless, in agreement 
with Weber et al. (109). Schimizu et al. (194) found that metabolite ratios, in particular Cho 
levels, correlated with Ki-67 levels in gliomas. Ki-67 labeling is used in histologic examination 
as a marker for cellular proliferation. Therefore, the Cho/Cr and Cho/NAA ratios should be 
helpful in the grading of gliomas (73). Zhang et al (195) found a strong positive correlation 
between Cho/NAA ratio and MMR-2 (matrix metalloproteinase-2). It has been proved that 
the infiltrating growth pattern of astrocytoma is closely associated with the antigen MMR-2 
(196,197). 
 
The sensitivity of tumoral Cho/NAA ratio in the differentiation of LGGs from HGGs was of 
40%, indicating a low true-positive rate and high-false negative rate. However, the high 
specificity (96.4%) means that only rarely were LGGs falsely identified as HGGs. These results 
are in disagreement with those of a previous report (73). In this study, the sensitivity of 
Cho/NAA in glioma grading was 96.7%, however the specificity was very low (10%); however, 
the authors considered that high sensitivity in identifying HGGs is more important than high 
specificity because of the relatively fewer cases of LGGs and the more serious consequences 
of false-negative findings. In a previous study (109), the AUC was 68% in differentiating 
glioblastoma from grade II gliomas, which is comparable to our AUC of 64% in differentiating 
HGGs from LGGs. As a single parameter, the tumoral Cho/NAA ratio yielded an accuracy of 
84.5% in our study. This is certainly not sufficient to replace histopathology as the gold 
standard. 
 
One of the most interesting results of our study was the elevation in peritumoral Cho/Cr and 
Cho/NAA metabolite ratios in relation to grading. The peritumoral Cho/NAA and Cho/Cr ratio 
were significantly higher in HGGs than in LGGs. Weber et al. (109) demonstrated pathologic 
spectra with elevated Cho levels and thus increased Cho/NAA ratios in the perifocal T2-
weighted hyperintense region in all cases of gliomas. Nelson et al. (198,199)  have shown in 
several studies that MRSI patterns suggestive of tumor can be found outside the borders of 
contrast enhancement in HGGs. McKnight et al. (57) reported that some of these areas of 
edema identified on T2-weighted  imaging showed Cho/NAA ratios greater than 2, which is 
within the range seen with tumors. 
 
The sensitivity of peritumoral Cho/Cr in glioma grading (LGGs versus HGGs) in our study was 
83.3%, indicating a high true-positive rate and low false-negative rate. Hence, if the 
peritumoral Cho/Cr ratio is above 1.35, there is a high probability that the tumor will be a 
HGG. Conversely, when peritumoral Cho/Cr is below 1.35, the tumor is unlikely to be HGG. 
The high NPV (97.6%) is likewise a significant finding, as gliomas with low peritumoral Cho/Cr 
(<1.35) are unlikely to have high-grade components. Hence, it is an excellent tool for 
excluding the presence of a HGG. The sensitivity of peritumoral Cho/NAA in the 
differentiation of LGGs versus HGGs was 100% in this study, demonstrating that metabolite 
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ratios can be useful in determining tumor grade. To the best of our knowledge, we could not 
find any published reports that indicated the use of diagnostic examination performance of 
peritumoral metabolite ratios for predicting glioma grade. 
 
Integration of preoperative MRSI and Diffusion imaging in predicting glioma grade 
 
The results of the step-up logistic regression analysis including all four parameters showed 
that the combination of DWI and MRSI increases the accuracy of preoperative imaging-
assisted grading of gliomas when compared with DWI or MRSI alone in determining glioma 
grade (LGGs and HGGs). The grading accuracies of the one-parameter (minimum ADCt), one-
parameter (peritumoral Cho/Cr), and four-parameter (mean ADCt value, maximum ADCt 
ratio, peritumoral Cho/NAA and Cho/Cr ratio) methods were 75.7%, 84.9%, and 92.5%, 
respectively. The sensitivity of combined DWI variables and MRSI variables in the 
determination of a HGG in our study was 91.5% which indicated a high true-positive rate and 
low false-negative rate. On the basis of our results, we believe that the added value of DWI 
and MRSI may be helpful to establish a correct grading of patients with gliomas, and in the 
process of therapeutic decision making. 
 
We propose that, in patients with a poor functional status and an unfavorable lesion 
location, use of the combined DWI and MRSI method can offer the clinician, patient and 
family an accurate diagnosis of high-grade glioma without needing a biopsy. We do not 
advocate the replacement of biopsy in all patients; instead our data suggest a specific role 
for the use of combined DWI and MRSI in HGG diagnosis that has both high accuracy and 
added benefit. In a recent paper, Fellows et al. (200) reported that the combined use of 
neuroradiology and MRS provides an accurate, noninvasive, treatment limiting diagnosis of 
GBM. The authors proposed that in patients with a low Karnofsky score and for a highly 
eloquent, undesirable location, that have a radiological diagnosis of GBM combined with a 
MRS high grade lesion the requirement for a confirmatory biopsy can be questioned and 
instead an alternative to biopsy offered to the patient and family. Biopsy is invasive, not 
without risks, and delays the start of either palliative radiotherapy or care (200). The 
principal risk of a biopsy is hemorrhage. Mortality in most series is 1-2% and neurological 
morbidity 3-5% (201). Neurosurgical admission is stressedful for the patients, and histology 
is inconclusive in up to 8-12% of patients (202,203). 
 
Correlation analysis 
 
Our results revealed a weak inverse correlation between minimum ADCt value and degree of 
malignancy. Previous studies have reported that ADC is inversely correlated with tumor 
cellularity (51,187). In a recent paper, Chang et al. (187) have shown that while this may be 
the case for area of macroscopic tumor within the enhancing volume of grade IV glioma, it is 
not consistent with the values in grade II and grade III glioma. Catalaa et al. (204) observed a 
negative correlation between mean ADC and mean Cho for patients with newly diagnosed 
grade IV gliomas, but not for grade II or grade III gliomas. Khayal et al. (205) were unable to 
detect a correlation between Cho levels in the contrast enhancement or necrotic core and 
ADC in grade IV gliomas, but they found a negative correlation between median Cho and 
ADC in the non-enhancing lesion and the overall T2-hyperintensity. In our study, we did not 
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find significant correlation between minimum ADCt value and tumoral Cho/NAA ratio for 
patients with LGGs and HGGs. 
 
One possible interpretation of such findings is that ADC values are influenced by a 
combination of difference in tissue architecture and tumor cell density (187). In low grade 
astrocytoma, where the emphasis is on the breakdown of the normal structure of white 
matter, the dominant process gives a high ADC, but with a reduction in NAA and moderate 
increase in Cho that is caused by infiltrative tumor. In HGG the majority of contrast 
enhancing lesion has been completely replaced by tumor cells and so low ADC reflects high 
tumor cell density, as well as elevated Cho and low NAA (high CNI) (187). Chang et al. (187) 
reported that while the CNI indicates the presence of tumor and is valuable for defining the 
extent of the metabolic lesion, it can be very high in all tumor grades and its presence does 
not necessarily mean that the tumor is going to progress rapidly. 
 
Perfusion and permeability MRI in the differentiation of glioblastoma 
multiforme and brain metastasis (Paper IV). 
 
Distinction of brain metastases from HGGs by conventional MRI remains an important 
unsolved clinical problem (206). It is clinically important to distinguish GBM from a single 
brain metastasis, because medical staging, surgical planning, and therapeutic decisions are 
vastly different for each tumor type and can potentially affect the clinical outcome (16,17). 
 
Angiogenesis is the process of new blood vessel formation by endothelial cells from pre-
existing adjacent vessels (207). When primary tumors or metastases begin to grow beyond 
1-2 mm in diameter within the brain parenchyma the BBB becomes compromised both 
structurally and functionally (207, 208). In addition, tumor blood vessels are disorganized, 
irregular in caliber, tortous, and do not have specialized features of normal arterioles, 
capillaries or venules (209). The capillary ultrastructure is markedly different between GBM 
and a brain metastasis (160,210). Vascular permeability and vascular perfusion imaging 
methods can provide an insight into the tumor vasculature and angiogenesis. 
 
Assessment of microvascular permeability: GBM versus metastasis 
 
Permeability can be assessed from DSC images within certain limitations. Such 
measurements are possible because two dominant features contribute to the time signal-
intensity curve generated from DSC-based data after rapid passage of a bolus on Gd-based 
contrast material. The predominant feature is the so-called K1 effect, which represents the 
effect of intravascular contrast material; this effect is used to define rCBV maps. However, 
another feature contributes to the time signal-intensity curve, the so-called K2 effects 
generated by T1-shortening effects of the extravascular component of the infused contrast 
material. The K2 effects can be analyzed separately from the K1 effects to produce maps that 
depict relative degrees of leakage of contrast material (102). In this study, we have 
calculated MVL expressed as the leakage coefficient K2. 
 
Our study showed that both maximum and mean MVL values were significantly higher in 
GBMs than those in brain metastases. Weber et al. (109) using the exchange rate constant 
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Kep that reflects the rate constant between the extracellular space and the blood plasma, did 
not find a significant difference between GBMs and metastases. Lüdermann et al. (211) 
found that the mean fast permeability component was in the same range as that for gliomas 
(grades II-IV gliomas were grouped together in this study).  
 
The significant difference in MVL values between GBMs and metastases is probably due to 
multiple factors. However, in practice the exact pathologic mechanisms accounting for 
imaging changes in permeability and in blood volume are not known. It has been well 
established that blood vessel structure and function become markedly abnormal in brain 
tumors  (212,213). The cause of this vessel morphological changes is probably cancer-
induced alteration of the vessel wall. Such alterations include modification of the basement 
membrane, endothelial cell fenestrae, reduction of pericytes and smooth muscle, and the 
formation of blind saccular extension. This vessel wall disruption also often produces a 
“leaky vessel”, in which intravascular contents leak into interstitial tissues (101). GBMs are 
known to have blood vessels of increased diameter, high permeability, thickened basement 
membrane, and high proliferation of endothelial cells (212). Vascular endothelial growth 
factor (VEGF) is one of the best characterized permeability factors expressed in gliomas and 
has been shown to directly contribute to BBB breakdown in gliomas (207,212). Carbonell et 
al. (214) have demonstrated that the vascular cooption (the propensity of metastatic cells to 
grow along the exterior of pre-existinng vessels of the CNS) is the predominant form of 
vessel use by tumor cells during early experimental brain metastases and in human clinical 
specimens reflecting early stages of the disease. Other factors than can influence the 
measurements of microvascular permeability include luminal surface area and hydrostatic 
interstitial, and osmotic gradients across the endothelium (215). 
 
ROC analysis yielded AUC values of 0.72 (maximum MVL) for discrimination of GBMs from 
metastases. The relatively low specificity (63%) means that false-positive rates are relatively 
high and true-negative rates are correspondingly low. In other words, some GBMs will be 
falsely identified as metastases, indicating that caution in the clinical setting should be 
considered. 
 
To the best of our knowledge, this is the first study that systematically compared MVL 
determined by the first-pass T2* method in the differentiation between GBMs and 
metastases. Further refinements in the different techniques for measuring of MVL are 
needed. Prospective validation of these preliminary results is of course required to more 
confidently establish the differentiation between GBMs and metastases using MVL 
measurements. 
 
Magnetic resonance perfusion in the tumoral region: GBM versus metastasis 
 
In this study, we did not find statistically significant difference between rCBFt measurements 
when GBMs were compared with metastases, in agreement with a study by Sentürk et al. 
(216) and Weber et al. (109), but in this case perfusion (CBF) was measured by arterial spin 
labeling (ASL). Cha et al. (164) showed that a percentage signal recovery less than 66% 
within the contrast-enhancing region of the tumor had a specificity of 100% and a sensitivity 
of 69% in correctly identifying that a tumor is not a GBM. 
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Magnetic resonance perfusion in the peri-enhancing region: GBM versus metastasis 
 
The differences of rCBVe, rCBVt/e, rCBFe, and rCBFt/e between GBMs and metastases were 
statistically significant (p<0.0001). The GBMs had significantly higher rCBFe values than 
metastases, in agreement with Weber et al. (109), and the metastases had significantly 
lesser rCBVe values than GBMs, in accordance with previous observations 
(75,106,182,216,217) supporting the hypothesis that perfusion MRI can detect infiltration of 
tumor cells in the perienhancing region. Furthermore, Cha et al. (164) demonstrated that the 
first-pass bolus peak height and percentage recovery of signal in the peritumoral region on 
T2*-weighted DSC images could differentiate between HGGs and solitary metastases. 
 
This difference in the peritumoral CBF/CBV can, in part, be explained by the difference in 
pathophysiology of tumor-related edema. Cerebral edema is defined as an increase in brain 
volume owing to an increase in brain water and sodium content (218,219). The two main 
types of cerebral edema are cytotoxic edema and vasogenic edema. Vasogenic edema, 
typically associated with primary and metastatic brain tumors, is caused by increased 
vascular permeability (218). One function of the BBB is to prevent leakage of plasma fluid 
and proteins into the brain parenchyma. The BBB is composed of a complex network of 
endothelial cells, pericytes, and astrocyte foot processes that form tight, almost 
impermeable, junctions (218). In conditions associated with BBB disruption (for example, 
metastatic or primary brain tumors), extravasation of plasma fluid and proteins occurs 
across the disrupted BBB, which results in vasogenic edema and increased fluid pressure 
within the tumor (220). Histological studies of the BBB in primary and metastatic brain 
tumors reveal abnormal tight junctions, increased pinocytotic activity, and the presence of 
fenestrations. Additionally, the basement membrane is thickened and irregular with 
diminished interactions between pericytes and astrocytes (158,221). The result is a poorly 
functioning, hyperpermeable BBB with pores up to 500 nm in diameter, which allows the 
passage of plasma fluid into the CNS (222). 
 
In metastatic tumors, the peritumoral brain edema is thought to be essentially vasogenic in 
type and rich in plasma protein derived from leaking microvessels in or around the 
metastases (159). A most important pathogenetic mechanism of vasogenic edema is a 
disturbed vascular permeability that enables an indiscriminate escape of plasma proteins 
from the blood into the metastases or the peritumoral parts of the brain (159). In other 
words, in metastatic tumors, there is no histologic evidence of tumor beyond the outer 
margin of the tumor (158,169). In contrast to edema surrounding metastases, peritumoral 
edema associated with HGGs is characterized by extensive infiltration of tumor cells (170). A 
recent paper by Engelhorn et al. (168) showed that the so-called perifocal edema not only 
includes invading tumor cells but also is associated with glial alterations in vital brain tissue. 
Furthermore, Long et al. (161) did not find morphological evidence of increased permeability 
in microvessels around metastatic adenocarcinomas, whereas Stewart et al. (221) reported 
structural defects in endothelial tight junctions around human GBM. The latter findings may 
be related to the ill-defined margin in GBM and cell infiltration in surrounding brain. 
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In our study, the best CBF parameter that enables distinction between GBMs and metastases 
was CBFe, with a sensitivity, specificity, PPV, and NPV of 89%, 89%, 81%, and 94%, 
respectively. Weber et al. (109) reported with ASL a sensitivity, specificity, PPV, and NPV of 
100%, 71%, 94%, and 100%, respectively. Thus, we believe that rCBFe could be used in the 
clinical decision-making process to distinguish GBM from metastases. In our study, the best 
CBV parameter obtained for the distinction between GBMs and metastases was rCBVe with 
an AUC of 0.98. Our results were similar to the findings of Bulakbasi et al. (217), in which 
AUC was 0.955. The sensitivities of rCBVe and rCBVt/e of 95% and 89%, respectively, in this 
study confirm that these hemodynamic parameters can be useful in the distinction between 
GBMs from metastases. 
 
Correlation analysis 
 
In our study, there was a modest correlation between rCBVt and rCBFt ratios with the high 
Spearman`s rank correlation coefficient of 0.35, p=0.005. However, several authors 
(216,223) found a strong correlation between these two parameter values with the high 
Spearman`s rank correlation of 0.748 and 0.762, respectively, but including a miscellaneous 
of tumors (216) or HGGs and LGGs (223). Although, Weber et al. (109) did not find 
correlation between these two parameters in all tumor entities (LGGs and HGGs, PCNSL, 
metastases, meningiomas, and miscellaneous non glial circumscribed tumors). According to 
Gerstner et al. (15) the relationship between CBV and CBF is complicated and a distinction 
must be made between the two measurements as they may not always correlate. An area of 
tumor may contain an increased volume of blood because of increased vessel size or number 
of vessels, but the blood flow through that area maybe slow and inefficient because of the 
underlying abnormal tumor vasculature. 
 
In the current study, we found a weakly negative, statistically insignificant relationship 
between rCBVt and MVL and rCBFt and MVL for all brain tumors. Our correlation results 
indicate that MVL, rCBVt, and rCBFt may be measuring different aspects of tumor 
angiogenesis. In a recent paper, Jain et al. (224) have reported that CBV showed a significant 
positive correlation with microvascular density (MVD), whereas permeability surface area 
(PS) showed a significant positive correlation with microvascular cellular proliferation 
(MVCP) in gliomas, suggesting that these two perfusion parameters represent different 
aspects of tumor vessels. 
 
Perfusion and permeability MRI in glioma grading (Paper V). 
 
Gliomas, the most common primary brain neoplasms in adults, are very heterogeneous 
tumors. HGGs can be highly invasive and extremely vascular tumors (225). The formation of 
new blood vessels through the prosess of angiogenesis and the invasion of glioma cells 
through white matter tracts are believed to be two major components of glioma biology 
(212). Malignant brain tumors are characterized by neovascularity and increased angiogenic 
activity, with a higher proportion of immature and highly permeable vessels (225). The 
current standard for tumor grading is histopathologic assessment of tissue, which has 
inherent limitations, such as sampling error, intraobserver variation, and a wide variety of 
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classsification systems that are available, the most common of which is the WHO grading 
system (111). 
 
In vivo perfusion imaging techniques provide additional information regarding tumor 
physiology and hemodynamics, which may help in better characterizing glioma malignancy 
and may also overcome some of the limitations of histologic grading and conventional 
morphologic imaging (225). 
 
Magnetic resonance permeability in predicting glioma grade 
 
MVL expressed as the leakage coefficient K2 is proportional to the leakage (PS), where PS is 
the product of permeability surface area (100). In physiological terms, PS is the rate at which 
contrast agent flows into the extravascular tissues and is related to another commonly 
stated parameter of vascular leakage, the Ktrans (226). 
 
In this study, we found that maximum MVL (MVLmax) was significantly different between all 
tumor grades, most pronounced between grades II and IV, grades II and III-IV. In one study, 
the mean Ktrans values for grade IV gliomas was greater that the mean of the Ktrans values for 
either grade II or III gliomas, but no significant difference was noted between grades II and III 
using the first-pass T2*-weighted method (227). Patankar et al. (228) found significant 
differences between grades II and IV, but no significant diferences between grades II and III, 
and III and IV using the Ktrans variable. Other studies have shown that using the parameter 
Kep, significant differences were noted only between grade II and GBM (grade IV) (109). Jain 
et al. (225,226), apart from differentiating low-and high-grade gliomas, could also 
differentiate a high-grade tumor group into grade III and grade IV on the basis of PS 
measurements. This result is in keeping with the current WHO guidelines of including MVCP 
as a diagnostic criterium of grade IV, but no for grade III astrocytic tumors, suggesting that 
PS measurements could show better correlation with MVCP and, hence, could be an imaging 
biomarker of more immature and leaky blood vessels. Increased angiogenesis in grade IV 
tumors is characterized not only by an increased number of vessels compared with grade III 
astrocytic tumors, but also by association with disproportionate lengthening, increased 
pliability, endothelial cell proliferation, and irregular shape, which can explain the difference 
in perfusion parameters for grade IV compared with grade III tumors. 
 
The significant differences in MVL for all three grades are probably due to multiple factors. It 
has been established that permeability of glioma vessels is enhanced with respect to those 
in normal brain tissue, although the degree to which this is true is complex and varies with 
respect to time and location (207). Permeability is varied, even within a simple tumor in the 
brain, and this heterogeniety of permeability contributes to uneven distribution of transport 
products, such as oxygen and chemotherapeutics within the tumor bed (212). VEGF is one of 
the best characterized permeability factors expressed in gliomas and has been shown to 
directly contribute to BBB breakdown in gliomas (207). Increased permeability of tumor 
blood vessels by factors such as VEGF results in elevated interstitial pressure and significant 
intracerebral edema, a hallmark of human gliomas (212). In a recent paper, Bulnes et al. 
(229) described that during development of gliomas, the microvasculature becomes 
aberrant, undergoing a sequence of adaptive changes, which involve the distribution and 
permeability of vessels. Results in this study showed that microtumors (LGGs) displayed 
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homogeneous angioarchitecture composed of simple and midly dilated vessels similar to 
normal tissue, whereas macrotumors (HGGs) showed different patterns, following a gradient 
from the neoangiogenic border to the hypoxic core. The tumor core contains scarce, huge, 
and dilated vessels, the peripheral tissue shows light dilated vessels, and the border area 
displays glomeruloid vessels strongly positive for VEGF. 
 
ROC analysis yielded AUC value of 85.9% (MVLmax) for discrimination of grade II from grades 
III-IV. In the study of Patankar et al. (228), the AUC for Ktrans was 97.9%. The sensitivity of  
MVLmax  in our study was 96.7%, indicating high true-positive and low false-negative rates, 
the high NPV (85.7%) for MVLmax is likewise a significant finding, as glial tumors with low 
MVLmax (<0.555) are unlikely to have high-grade components. ROC analysis yielded AUC 
values of 88.5% (MVLmax) for discrimination of grade II from grade IV. The sensitivity and 
NPV of MVLmax  in our study was 100%, indicating that this parameter is an excellent tool for 
the discrimination of grade IV from grade II.  
 
The relatively low specificity (61.1%) of MVLmax for discrimination of grade II from grade III, 
and the low specificity (42.9%) of MVLmax for discrimination of grade III from grade IV, means 
that false-positive rates are relatively high, and true-negative rates are correspondingly low. 
 
Predicting glioma grade: Perfusion 
 
In our study, rCBVt was significantly different for all three grades, in accordance with other 
authors (215,228). Recently, the relationtship between CBV and tumor grade has been 
reinforced using CBV measured by VASO imaging (230) and by DCE-CT (231). More 
importantly, rCBV maps from DSC MRI can identify areas of malignant transformation or 
tumor dedifferentiation in at risk primary low grade lesions before they are visible on 
conventional imaging. This allows for more accurate targeting of stereotactic biopsies, and 
potentially more accurate estimation of tumor grade (80). We found that rCBVe values were 
quite effective in differentiation of grade II from grade IV, grade II from grades III-IV and 
grade III from grade IV, in disagreement with Weber et al. (109). This difference in the 
peritumoral CBV can, in part, be explained by the difference in pathophysiology of tumor-
related edema. Peritumoral edema associated with high-grade gliomas is characterized by 
extensive infiltration of tumor cells (170). 
 
In our study, rCBFt was able to distinguish between all pair of tumor grades, except grade III 
versus grade IV. Weber et al. (109) and Law et al. (232) found significant difference between 
grade III and GBM, but in the first case , perfusion (CBF) was measured by ASL, and in the 
second case, absolute CBF values were used. In the current study, the rCBFt/e parameter 
values differed significantly between grade III and grade IV. 
 
ROC analysis yielded AUC value of 97.4% (rCBVt) for discrimination of grade II from grades 
III-IV. In the study of Patankar et al. (228), the AUC for rCBVt was 96.64%. The sensitivity of 
rCBVt in our study was 98.4%, indicating high true-positive and low false-negative rates. 
Hence, if the rCBVt is above 2.935, there is a high probability that the tumor will be a high-
grade glial tumor (III-IV). The rCBVe values tended to increase with tumor grade, which 
reflects more diffuse infiltration of adjacent brain structures with higher tumor grades. 
However, the relatively low specificity (60%) means that false-positive rates are relatively 
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high, and true-negative rates are correspondingly low. On the other hand, Bulakbasi et al. 
(217) obtained a specificity of 100%. 
 
In our study, the best rCBV parameter that enables distinction between grades IV and II was 
rCBVt, with an AUC of 99.7%, similar to the findings of Weber et al. (109). The sensitivities of 
rCBVt and rCBVe of 100% and 95.6%, respectively, in this study confirm that these 
hemodynamic parameters can be useful in the distinction between grade IV and II. In the 
current study, the best CBF parameter was rCBFt, with a sensitivity of 97.9% and a NPV of 
91.7%. In the study of Weber et al. (109) using ASL, the sensitivity and NPV was 94% and 
78%, respectively. 
 
In this study, we were able to differentiate grade II from grade III with a high sensitivity 
(92.9%), but the specificity was relatively low (72.2%) by using the parameter rCBVt. The 
sensitivity of rCBVt, rCBVe and rCBFt/e in our study was >90% for discrimination of grade IV 
from grade III; however, the specificity was low. 
 
Correlation analysis 
 
Tumor angiogenesis is a complex multistep process and is characterized morphologically by 
an increase in the number of blood vessels, endothelial cell proliferation, and development 
of abnormal tumor vessels. Morphologic assessment of angiogenesis does not form the basis 
of histologic glioma grading under present WHO classification. However, the degree of 
angiogenesis is critical in assessing tumor grade, predicting tumor progession and 
recurrence, and hence patient prognosis (224,233,234,235,236). 
 
In the current study, we found a strongly positive statistically significant relationship 
between rCBVt and glial tumor grade, in accordance with previous studies (215,228,232). It 
is not surprising that rCBVt measurements are reliable correlated with tumor grade and 
histologic findings of increased vascular permeability (215). In a recent paper, Jain et al. 
(224) have shown a strong correlation of tumor blood volume with MVD. The authors 
reported that the association between MVD and tumor aggressiveness can be explained by 
the following: 1) Solid tumors are composed of 2 interdependent components, which include 
the malignant cells and the stroma that they induce. 2) Endothelial cells in this stromal 
component stimulate the growth of tumor cells; thus, the more intratumoral vessels there 
are, the more endothelial cells and paracrine growth stimulation will occur. 3) Intratumoral 
MVD is a direct measure of the vascular window through which tumor cells pass to spread to 
distant sites (224,236). 
 
The correlation between the tumor grade and rCBF showed only a moderately positive 
statistically significant relationship. In one study, using absolute CBF was found a better 
correlation with tumor grade (232). 
 
The correlation between grade of glioma and Ktrans has been reported with conflicting results 
(215,237,238). However, most of the studies have shown moderate to weak correlation 
between Ktrans and glioma grade (239). Our MVLmax values progressively increased with glial 
tumor grade, and the significant correlation we observed between our MVLmax and glial 
tumor grade validates the T2*-weighted technique for estimating MVL, expressed as the 
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leakage coefficient K2. In a recent paper, Jain et al. (224) found a significant positive 
correlation between PS and MVCP. MVCP is defined as hyperplasia of cells in the wall of 
capillaries, small arterioles, and small veins and is a well-known feature of HGGs, especially 
GBMs. MVCP in glial tumors has been attributed to exuberant proliferation of endothelial 
cells (224). In the study by Jain et al. (224), MVCP showed a statistically correlation with PS 
and not with CBV, suggesting that MVCP is associated with leakies tumor vessels and regions 
of increased PS within a heterogeneous tumor might indicate more immature vasculature, 
whereas higher CBV regions might indicate hyperperfusion with more mature vessels. 
 
In our study, rCBVt was moderately and positively correlated with rCBFt. A previous study 
(240) has found a higher level of correlation between these two parameters. However, in 
another study (109), no strong correlation between rCBF and rCBV was obtained. According 
to Gerstner et al. (5), the relationship between CBV and CBF is complicated, and a distinction 
must be made between the two measurements as they may not always correlate. An area of 
tumor may contain an increased volume of blood because of increased vessel size or number 
of vessels, but the blood flow through that area may be slow and inefficient because of the 
underlying abnormal tumor vasculature. 
 
We found a moderate correlation between rCBVt and MVLmax (r=0.440; p<0.0001). On the 
other hand, Law et al. (215) found only a modest correlation between rCBV and Ktrans 
(r=0.266; p=0.023). Finally, rCBFt and MVLmax correlated only weakly positive (r=0.192; 
p=0.090). 
 
There are potentially a number of confounding factors. First, in situations in which capillary 
permeability is very high, the flux of contrast agent into the extravascular space is limited by 
the flow rate (5,241). Second, in states of very low permeability, contrast agent cannot leak 
into the extravascular space easily (5,241). Third, the region of maximal CBV, CBF from the 
rCBV and rCBF map may not always correspond to the region of maximal permeability (215). 
Fourth, steroid use is an important confounder of both tumor permeability and blood 
volume measurement (242). Steroids decrease the permeability of the BBB. Steroids can 
result in less contrast agent extravasation at MRI studies and, thus, less of a confounding 
leakage effect for rCBV calculations (98). Fifth, a number of physiological factors may 
influence DSC MRI measurements. For instance, each subject`s cardiovascular and renal 
status may influence the shape and quality of the contrast bolus arterial input and/or the 
contrast agent clearance from the blood pool and extravascular extracellular space (99). 
 
Finally, the measurements of rCBV, rCBF, and the MVL may depend on the DSC MRI 
acquisition and postprocessing methods, due to BBB disruption and resulting T1-weighted 
leakage and T2-and /or T2*-weighted imaging residual effects (99). In a recent paper, 
Paulson and Schmainda (98) obtained reliable and robust results of tumor rCBV using the 
preload-postprocessing correction and dual-echo approaches. In a very recent paper, Hu et 
al. (99) combining preload dosing (PLD) and baseline substraction (BLS) improved accuracy in 
the differentiation of posttreatment radiation effect and tumor growth. However, no general 
consensus exists regarding which PLD amount enables the most accurate rCBV estimation, 
and what optimal protocols are necessary at higher field strengths. Additionally, T2/T2*-
weighted imaging residual effects and the need for appropriate correction methods, such as 
BLS, may be related to PLD amount, further confounding accurate rCBV measurement 
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(96,98,100). Other factors, such as incubation time, may impact the adequacy of T1-
weighted leakage correction and rCBV measurement accuracy (96,100,245). These DSC 
methods should also take into consideration the recent linkage between nephrogenic 
systemic fibrosis and total contrast dosage (246). Nonetheless, the method used in our study 
showed a very good diagnostic accuracy in grading glial tumors, as well as previously 
reported in the differentiation of GBM from metastasis (247), suggesting the clinical 
robustness of this technique. Recent studies have shown that DSC MRI without preload 
correction has potential to improve overall diagnostic accuracy in distinguishing glioma 
progession from postradiation change (248,249), and in the grading of gliomas (250). 
Furthermore, previous study findings have indicated that reducing the T1-weighted effects 
caused by administering contrast agent before DSC MRI causes increased T2*-weighted 
susceptibility effects, leading to a reduction in the postcontrast bolus baseline signal 
intensity (248,251,252,253).   
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Conclusions 
 
The general aim of this thesis was to characterize brain tumors using advanced 
neuroimaging, and the results can be briefly summarized as below: 
 
 In Study I, we demonstrate that ADC values and ADC ratios in peritumoral brain 
regions were not useful in determining the presence of peritumoral neoplastic cell 
infiltration; in other words, DWI cannot aid in the distinction of vasogenic edema 
surrounding metastases and meningioma from non-enhancing tumor infiltration in 
HGGs. We also demonstrated that the combination of four parameters resulted in 
improved diagnostic accuracy in the differentiation of metastases from HGGs. 
 
 In Study II, we demonstrate that MRSI can differentiate HGGs from metastases, 
especially with peritumoral measurements, supporting the hypothesis that MRSI can 
detect infiltration of tumor cells in the peritumoral edema. Moreover, we defined the 
role of MRSI in the clinical decision-making process, in terms of sensitivity, specificity, 
PPV, NPV, and accuracy. 
 
 In Study III, we demonstrate that combining DWI and MRSI increases the accuracy of 
preoperative imaging in the determination of glioma grade. MRSI had superior 
diagnostic performance in predicting glioma grade compared with DWI alone. 
 
 In Study IV, we demonstrate that vascular permeability (MVL, expressed as the 
leakage coefficient K2) and vascular perfusion (CBV, CBF) derived from DSC MRI can 
be helpful to discriminate GBMs from solitary metastases, in particular when values 
from peritumoral edema areas are used, supporting the hypothesis that perfusion 
MRI can detect infiltration of tumor cells in the peri-enhancing region. In this study, 
we report for the first time the diagnostic examination performance of MVL 
determined by the first-pass T2* method in the differentiation between GBMs and 
metastases. 
 
 In Study V, we identified differences among all tumor grades for the parameters 
rCBVt and MVLmax as determined by the first-pass T2*-weighted technique. 
Compared with MVLmax, rCBVt values were more predictive of glial tumor grade 
between grade II and grades III-IV or IV. In this study, we demonstrate that rCBVt 
correlated strongly with tumor grade and moderately positive with rCBFt, but the 
correlation between MVLmax and rCBVt or rCBFt was moderate or weakly positive 
respectively, suggesting that these hemodynamic parameters may be related to 
different aspects of tumor angiogenesis. 
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Future perpectives 
 
Neuroradiology of brain tumors has changed significantly during the past few years. 
Whereas a morphology-based description was the principal means of categorizing and 
differentiating brain neoplasms in the early years, functional, hemodynamic, metabolic, 
cellular, and cytoarchitectural analyses of the tumor and the surrounding brain are now 
major tools in the neuroradiological work-up of these diseases. 
 
Future directions for diffusion imaging 
 
DTI is the latest application of DWI, in which white matter integrity can be depicted on a 3D 
map (18,254). DTI and tractography are promising, noninvasive tools to study the white 
matter tracts and, with further development and validation, are likely to become an 
important and integral part of preoperative planning of brain tumors in the future (18). 
Preoperative tractography can indicate the locations of the important white matter tracts 
relative to the tumor, and thereby guide the surgical approach and the intraoperative 
stimulation (117). Furthermore, diffusion imaging offers potential as a biomarker of 
treatment response because it is sensitive to tissue-tumor cellular density and organization 
(118), allowing for early detection of therapeutic-induced changes in tumor morphology 
(255), and providing a more accurate prediction of patient survival (256). 
 
Future directions for MR spectroscopy and metabolic imaging 
 
MRS at 3 T will allow higher spectral quality, better peak separation, quantification, or even 
peak identification, higher spatial resolution, or fast MRSI. This benefit will result in 
significant new applications for neuro-MR spectroscopy, such as whole brain MRSI, ultrahigh 
resolution or dynamic application (65). The contribution of MRSI will continue to take 
increased prominence and importance in the definition of biopsy target, tumor classification, 
identification of active tumor and tumor invasion, delineation of the target volume for 
radiation therapy, monitoring of therapy and posttherapy evaluation, in the prediction of 
survival and the integration in multimodality imaging (68). Finally, robust and automated 
procedures are needed to collect the data, analyze the spectra and display the results in a 
timely fashion. 
 
Future directions for magnetic resonance perfusion and permeability imaging 
 
Currently, DSC is the most frequently used perfusion MRI technique for neuro-oncological 
issues. Whether the role of ASL technique might increase with the more widespread use of 3 
T scanners remain an open question (257). Despite the challenges associated with ASL, it 
remains a desirable technique due to the absolute measures of CBF it produces, and the fact 
that endogenous Gd contrast agents are not required (90). Monitoring novel 
antiangiogenesis treatment approaches using perfusion and permeability imaging 
techniques that can visualize microvascularity characteristics of tumors will gain further 
importance during the next few years in routine clinical work (257). Meanwhile, the 
contribution of MR perfusion and permeability will continue to take increased prominence 
and importance in differential diagnosis of cerebral tumors, in predicting glioma grade and 
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type, in predicting transforming of LGGs, in predicting therapeutic respons and prognosis in 
HGGs, and in distinguishing tumor recurrence and radiation necrosis (90). 
 
Another interesting research field will be the comparison of genomic expression profiles of 
brain tumors with features of morphologic and functional imaging. In summary, the various 
functional techniques may not be competing with each other but may give complementary 
information on various pathophysiological aspects. In the next few years, research will have 
to define which “mixture” of techniques to choose for which neuro-oncological question in a 
clinical setting with acceptable acquisition time (257). 
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